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Autosomal Polycystic Kidney Disease (ADPKD) is one of the most common inherited diseases with 
an incidence of 1 in 400 to 1 in 1000 in Caucasians.1-4 In 50% of the ADPKD patients the disease 
leads to end stage renal disease (ESRD) around the age of 55 years and patients require dialysis 
and renal transplantation. In fact, ADPKD accounts for up to 10% of the ESRD cases.5 ADPKD is 
characterized by the formation of fluid filled cysts in both kidneys eventually replacing almost all 
normal renal parenchyma leading to a decline in renal function (Fig. 1). The disease is, however, 
a systemic disease. Extra-renal manifestations are hypertension, cardiac valvular abnormalities, 
cerebral aneurysms and cysts in liver and pancreas.6
Figure 1. Polycystic kidney showing many cysts and fibrotic tissue.
Genetics of ADPKD
In 85% of the ADPKD patients the Polycystic Kidney Disease 1 (PKD1) gene, encoding the protein 
polycystin-1 (PC1), is mutated. In the remaining 15% of the patients the disease is caused by 
a mutation in the Polycystic Kidney Disease 2 (PKD2) gene, encoding polycystin-2 (PC2).7-9 The 
PKD1 gene is located on chromosome 16 and contains 46 exons, spanning 50 kb of genomic 
DNA, encoding a large 14.1 kb mRNA transcript. PKD2 has 15 exons, spanning 68 kb of genomic 
sequence, encoding a 5.1 kb mRNA transcript. 
No mutation hot spot has been found for PKD1 and PKD2, which means that mutations are 
spread throughout the entire gene.10
The polycystin proteins
PC1 protein is a large transmembrane glycoprotein of 4303 amino acids. It has a large extracellular 
N-terminal domain, 11 transmembrane domains and a short cytoplasmic C-terminus.11-13 The 










































interactions. In addition, the extracellular part contains a proteolytic G protein-coupled receptor 
(GPCR) proteolytic site domain (GPS) that was shown to be functionally active; cleavage activates 
signal transducer and activator of transcription-1 (STAT-1) and induces tubulogenesis in vitro.14 
The intracellular C-terminus of PC1 contains a coiled-coil domain that interacts with PC215-17 (Fig. 
2). The C-terminus has also been shown to be cleaved at least two different sites, generating 
two products. These products can interact with transcription factors, β-catenin or STAT6, and 
translocate into the nucleus to modulate gene expression.18, 19
PC2 is with 968 amino acids a smaller protein than PC1. This protein forms a nonselective cation-





Polycystin-1 (PC1) Polycystin-2 (PC2)
Figure 2. Schematic representation of polycystin-1 and polycystin-2 and the different domains. 
The polycystins are abundantly expressed in renal tubular epithelial cells where a balanced level 
of PC1 and 2 is required to maintain renal epithelial architecture. The polycystins are localized 
in several sub-cellular compartments such as the primary cilium, cell-cell contacts and cell 
extracellular matrix (ECM) contacts. 
The primary cilium is a cellular organelle that protrudes from the plasma membrane in non-
dividing cells, with one of the two centrosomes, the basal body, at its base. A primary cilium can 
be found on almost, if not all, cell types. Also renal epithelial cells have a primary cilium, which 
protrudes into the tubule lumen where it is thought to sense the extra-cellular environment. 
PC1 and PC2 are considered to act as mechanosensors here; upon bending of the cilium, as the 



















































the cell is not exactly known. However, ciliary signaling seems to be involved in cyst formation as 
mutations in many ciliary proteins result in renal cyst formation.
At cell-cell and cell-ECM contacts, they form different multimeric protein complexes, modulating 
several signaling pathways, which in concert control essential cellular functions such as 
proliferation, apoptosis, cell adhesion, and differentiation.2 Disruption of any of these processes 
can lead to cyst formation, as demonstrated by a variety of mouse models.20-24
Mechanism of cyst formation
In general, ADPKD patients carry one inherited mutated allele of PKD1 or PKD2 (germ-line 
mutation), and one healthy PKD1 or PKD2 allele. It is thought that renal epithelial cells of patients 
function normally, but when the expression of PC1 or PC2 drops below a critical threshold, cysts 
arise. This decrease in expression can be caused by a somatic mutation in the remaining healthy 
allele, called a “second hit” or due to haploinsufficiency, stochastic fluctuations in gene expression 
as a result of the inactivation of one allele.25 Somatic mutations are often found in renal epithelial 
cells and increase with age.26 The second hit model is also in agreement with the fact that only 
1% of the nephrons is involved in cyst formation and that mice heterozygous for mutated Pkd1 
or Pkd2 don’t show renal cyst formation. Furthermore cysts of clonal origin have been observed.27 
Whereas the second hit model assumes that cystic epithelia lack PC1 or PC2 expression, the 
haploinsufficiency model fits with the expression of PC1 and PC2 in cystic epithelia that has been 
reported. However, it was also shown that overexpression of the polycystins results in cysts. This 
suggests that expression of polycystins within a critical window, not too high or too low, or a 
correct balance between PC1 and PC2 expression is required for normal tubular morphology.
Following the acquired misbalance of PC1 and PC2 it was hypothesized that these cells then 
become hyper proliferative and show deregulation of many signaling pathways resulting in 
depolarization, increased fluid transport and extracellular matrix production. 
However, complete inactivation of Pkd1 at adult age resulted in a mild cystic phenotype after 
3-5 months, while inactivation during renal development resulted in massive cystic kidneys after 
1 month.28, 29 As a result, it was hypothesized that developmental and/or proliferative status of 
renal epithelial cells was important for cyst formation upon complete Pkd1-gene inactivation. This 
hypothesis is further discussed in chapter 2 of this thesis and is part of investigation in chapter 3. 












































 Second hit  Hyper proliferation
 Haploinsuffiecy  Depolarization
 ECM production
Fluid transport
Figure 3. Schematic representation of the proposed mechanism of cyst formation in ADPKD. All tubular 
epithelial cells contain one mutated PKD1 or PKD2 allele and one unaffected allele. During life, in a subset 
of cells, protein levels of PC1 and/or PC2 become misbalanced due to a second hit or haploinsufficiency 
(dark grey). When these cells proliferate, cyst formation is initiated and many signaling pathways become 
deregulated. The epithelial cells become hyper proliferative and depolarized. Increased fluid transport into the 
isolated cyst contributes to expansion.
Signaling pathways involved in ADPKD
Many signaling pathways are modulated by PC1 or 2 or are implicated in ADPKD and cyst 
formation. Both PC1 and PC2 are expressed in several sub-cellular compartments such as the 
primary cilium, cell-cell contacts and cell-extracellular matrix contacts. They form different 
multimeric protein complexes in the cell, modulating several signaling pathways, which in 
concert control essential cellular functions such as proliferation, apoptosis, cell adhesion, and 
differentiation.2, 30 Additionally, reduced Ca2+ influx, cAMP accumulation and aberrant Ras/Raf/
ERK activation are implicated in cyst growth 31, 32 as well as activation of mTOR, PI3-kinase, and 
Jak2-STAT1/3 signaling.33-35 However, this thesis focuses on canonical Wnt signaling, the planar 
cell polarity signaling and the Hippo pathway.
Canonical Wnt signaling
The canonical Wnt signaling pathway, also known as β-catenin mediated Wnt signaling pathway, 
signals through binding of the Wnts ligands to the frizzled receptors. In the absence of Wnt-
ligands, β-catenin, an integral cell-cell adhesion adaptor protein as well as transcriptional co-
regulator, is targeted for degradation via the ubiquitin pathway by a destruction complex. This 
destruction complex contains APC and GSK-3β among others (Fig. 4A). 
Upon binding of Wnt-ligand, the protein Dishevelled is activated and GSK-3β is recruited away 
from the degradation complex. This allows for stabilization of β-catenin levels and subsequent 



















































target genes are C-myc, Axin2, CyclinD1, Cd44, Ppar-δ and Mmp7. In addition to canonical Wnt 
signaling, also non-canonical Wnt-signaling routes, independent of β-catenin were discovered. 
These non-canonical pathways have also been termed the Wnt/Calcium and Wnt/JNK pathways 
in vertebrates and planar cell polarity pathway in Drosophila. The Wnt/JNK and PCP pathways 























Transcription of Wnt target genes:
Axin2, C-myc, Mmp-7, CyclinD1, Cd44, Ppar
Figure 4. Simplified diagram of canonical Wnt signaling. (A) In absence of Wnt-ligand binding to the 
frizzled receptor, β-catenin is targeted for degradation via the ubiquitin pathway by the destruction complex 
containing APC, GSK3β and Axin. (B) In presence of Wnt-ligand binding, activated Dishevelled (Dvl) inactivates 
the destruction complex by recruiting GSK3β away from the destruction complex. β-catenin can now enter 
nucleus and mediate transcription of Wnt-target genes. 
Planar cell polarity signaling
Epithelial cells do not only show apical-basal polarity but also show orientation within the plane 
of the epithelial cell sheet. This is called planar cell polarity (PCP). 
Planar cell polarity is clearly visible on the wings of Drosophila where all the hairs point in the 
same direction (Fig. 5A). Mutations in the PCP pathways core components disturb this pattern 
(Fig. 5B). Also during renal development the PCP pathway is important; it ensures lengthening of 
the tubules while maintaining correct tubular diameter. Defects in PCP signaling may therefore 
cause an increase in tubular diameter.36, 37
The PCP pathway is the signaling pathway that affects planar polarization of cells and is also 
known as the non-canonical Wnt pathway in Drosophila. This pathway also includes the frizzled 
receptor and the protein Dishevelled as well as the cadherins Dachsous (Ds) and Four-jointed (Fj) 










































from Drosophila wing and eye, it is not exactly known how planar cell polarity executed and 
regulated in vertebrates. In vertebrates the regulation is more complex and planar polarization is 
influenced by more signaling cascades than non-canonical Wnt signaling as discussed in chapter 
2. 
A B
Figure 5. Planar cell polarity (PCP) in cells of the wing of Drosophila. (A) Normal PCP in wild type cells; hairs 
point in the same direction. (B) Disturbed PCP; hairs point in random direction. 
Hippo signaling pathway
Finally, the Hippo pathway is also a major subject in this thesis. The Hippo pathway has extensively 
been studied in Drosophila, where it is involved in control of cell proliferation and apoptosis.39-41 
In addition, an important role for the Hippo pathway has been suggested in the regulation of 
organ and tissue size control. Hippo pathway mutants show dramatic alterations in e.g. wing 
size.39-42 The pathway is named after the core pathway component, the kinase Hippo. Via several 
phosphorylation steps eventually, the non-DNA binding transcriptional co-activator Yorkie (Yki) 
is phosphorylated and retained in the cytoplasm. This prevents Yki target genes from being 
transcribed (Fig. 6A). 
The core components of the Drosophila Hippo pathway are well conserved and also function as 
tumor suppressors in mammals in addition to regulating growth in terms of organ size control.43 
In mammals, the Hippo signaling pathway exerts its actions by controlling the transcription of 
genes through the Yki ortholog YAP and its paralog TAZ (Fig. 6B).
FJ is not only involved in PCP signaling but is also a regulator of the Hippo pathway together with 
















































































Transcription of YAP target genes:
Proliferation anti-apoptosis
Figure 6. Simplified diagram of Hippo signaling in (A) Drosophila and (B) mammals. (A) The kinase Hippo is 
at the top of a cascade of phosphorylation events leading to the phosphorylation of the transcriptional co-
activator Yki. Thereby targeting it for degradation through ubiquitination and preventing nuclear localization 
of YAP. Thus diminished activation of the Hippo pathway leads to nuclear localization of Yki and transcription 
of Yki targets genes. (B) In mammals the Hippo pathway in general functions the same way as in Drosophila. 
Here the effector molecule of the Hippo pathway is called YAP.
Mouse models used in this thesis to study cyst formation and disease progression 
In order to study the mechanism of cyst formation and disease progression in ADPK, several 
murine models are available.45-54 To overcome embryonic lethality homozygous knock-out mice 
and to study tissue specific effects of Pkd1-inactivation, inducible Pkd1 and Pkd2 deletion mice 
have been created, using the Cre/LoxP system.28, 29, 55-59
The inducible Pkd1-deletion model
One of the models used in this thesis is the tamoxifen-inducible KspCad-CreERT2;Pkd1del2-11/lox2-11 
model. This is a model using the Cre/LoxP system; In this mouse model one Pkd1 allele contains 
a germ-line deletion; exons 2-11 are deleted (Pkd1del2-11). The second Pkd1 allele contains two 
LoxP sites which are located in introns 1 and 11 respectively (Pkd1lox2-11) The inactivation of the 
second Pkd1 allele is based on excision of exons 2-11 by homologous recombination mediated by 
the Cre-recombinase (Fig. 7A). When Cre-recombinase is not active, exons 2-11 are not excised, 










































The Pkd1del2-11/lox2-11 mice are crossed with mice that contain a construct encoding a genetically 
engineered Cre-recombinase that is driven by the kidney specific cadherin promoter (KspCad), 
thereby only expressing Cre in renal epithelial cells. In addition, this Cre-recombinase is modified 
in such a way that it is inactive in absence of the chemical compound tamoxifen (Cre-ERT2). 
Thereby, excision of the by loxP sites flanked sequence, i.e., inactivation of the gene, can be 
achieved at any desired time point by administration of tamoxifen. 
Thus, in the generated transgenic mouse model (Fig. 7B) the second Pkd1 allele can be inactivated 
in renal epithelial cells specifically at any desired moment using tamoxifen. 
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B
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Exon 1 Exon 12-46
+Pkd1del2-11
Figure 7. Schematic representation of the inducible Pkd1-deletion model. (A) Schematic representation of the 
Pkd1 allele containing loxP sites in intron 1 and 11. When the recombinase Cre is active, the part between 
the loxP sites is then excised. (B) The Pkd1 inducible conditional knockout model is generated by breeding 
mice containing one Pkd1del2-11 allele and one Pkd1lox2-11 allele with mice in which a modified Cre is expressed 
in renal epithelial cells. The modified Cre-recombinase becomes active in presence of tamoxifen. In this way 




















































The Pkd1nl,nl mouse model
The second mouse model that was used in this thesis, is the Pkd1nl,nl model. These mice are 
homozygous for mutated Pkd1. This mouse model shows reduced expression of the normal Pkd1 
transcript caused by the insertion of a selection cassette containing the neomycin resistance gene 
(neo) flanked by loxP sites in intron 1 of Pkd1. This results in alternative splicing leading to a 
mixture of normal and mutant transcript, the latter predicted to result in a premature translational 
stop60 (Fig. 8). 
These mice develop cystic kidneys within 3-4 weeks and also show extra-renal manifestations such 
as cysts in the liver and pancreas and dissecting aortic aneurysms were observed.60, 61 However, 
the severity of the phenotype and lifespan is dependent on the genetic background of the mouse 
strain as is discussed in chapter 6. 
neoEx 1 Ex 2 Ex 3Pkd1nl allele
mutant Pkd1nl transcriptsPkd1nl transcripts Ex 1 Ex 2Ex 3neo
+
normal Pkd1nl transcriptsEx 1Ex 2Ex 3
Figure 8. Schematic representation of the Pkd1nl allele containing a selection cassette containing the neomycin 
resistance gene (neo) flanked by loxP sites in intron 1 of Pkd1. Alternative splicing of Pkd1 results in a mixture 











































Chapter 2 of this thesis reviews the signaling pathways involved in the different phases of 
ADPKD pathogenesis. The initiation phase, with hyper proliferative epithelial cells as a hallmark, 
is followed by a phase of cyst growth and cyst expansion. Later on, proliferation of cystic epithelia 
ceases and interstitial fibrosis and inflammation become apparent. This literature review focuses 
on the initiation phase and the involvement of planar cell polarity (PCP) signaling pathway, while 
briefly discussing other signaling cascades involved during this and following phases. In this thesis 
the different phases, as described in chapter 2, are studied. In chapter 3 the initiation of cyst 
formation is studied. In contrast to patients with ADPKD, heterozygosity for mutated Pkd1 in 
mice does not lead to cyst formation. Complete inactivation of Pkd1 in kidneys of conditional 
knockout mice, however, induces massive cyst formation when Pkd1 deletion occurs when renal 
development is not completed fully and proliferation of tubular epithelial cells is present. This 
suggests a role for proliferation in cyst formation. We investigated the role of tubular epithelial 
proliferation in cyst formation by induction of renal injury in adult mice, thereby inducing epithelial 
proliferation as a result of repair. In addition, canonical Wnt-signaling (β-catenin mediated) as 
well as PCP signaling were investigated as these pathways are involved in cyst formation. 
In chapter 3 we used measurement of the position of the centrosome as read-out system for PCP. 
Chapter 4 describes in detail the method used for measuring centrosome position.
 The results in chapter 3 showed differential expression of a component of the PCP pathway 
and Hippo-signaling pathway. Therefore, in chapter 5 the involvement of the Hippo signaling 
pathway in cyst formation and growth is examined. The Hippo signaling pathway is known for its 
role in Drosophila organ size control and involvement in several forms of cancer. Because of these 
characteristics this pathway provides a potential additional participant and therapeutic target in 
cyst formation and growth.
The later phase of ADPKD pathogenesis is subject of investigation in chapter 6. Here ADPKD 
disease progression is studied in the Pkd1nl,nl mouse model on a mixed genetic background of 
50% C57Bl/6J and 50% 129Ola/Hsd. The prolonged survival of these mice, compared to survival 
previously reported for this model on full C57Bl/6J genetic background, allowed us to examine 
several aspects of disease progression such as changes in renal volume and renal function, 
fibrosis and inflammation. Finally, the results described in the individual chapters of this thesis are 
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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is an inherited systemic disease with 
intrarenal cystogenesis as its primary characteristic. A variety of mouse models provided information 
on the requirement of loss of balanced polycystin levels for initiation of cyst formation, the role of 
proliferation in cystogenesis and the signaling pathways involved in cyst growth and expansion. 
Here we will review the involvement of different signaling pathways during renal development, 
renal epithelial regeneration and cyst formation in ADPKD, focusing on planar cell polarity (PCP) 
and oriented cell division (OCD). This will be discussed in context of the hypothesis that aberrant 
PCP signaling causes cyst formation. 
In addition, the role of the Hippo pathway, which was recently found to be involved in cyst growth 
and tissue regeneration, and well-known for regulating organ size control, will be reviewed. The 
fact that Hippo signaling is linked to PCP signaling makes the Hippo pathway a novel cascade in 
cystogenesis. 
The newly gained understanding of the complex signaling network involved in cystogenesis and 
disease progression, not only necessitates refining of the current hypothesis regarding initiation 
of cystogenesis, but also has implications for therapeutic intervention strategies. This article is 






























































Polycystic kidney disease presents itself in many different forms. In this review we will focus 
on Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a systemic disease with 
intrarenal cystogenesis as its primary characteristic. Extra-renal manifestations are hypertension, 
cardiac valvular abnormalities, cerebral aneurysms, and cysts in liver and pancreas1. Usually, 
in young adults, only a small number of cysts can be detected ultrasonographically, whereas 
at middle age, thousands of cysts and fibrotic tissue have replaced almost all normal renal 
parenchyma and renal function declines.
In general, ADPKD patients carry one germ-line mutation and one normal PKD1, or PKD2 allele. 
Renal cysts develop from somatic inactivation of PKD1 or PKD2 by a ‘two-hit’ mechanism2. In 
addition, haploinsufficiency, stochastic fluctuations in PKD1or PKD2 gene dosage below a tissue-
specific threshold, may suffice to cause cyst formation3. Importantly, recent studies indicate 
that the picture can be more complex, since several families have been reported with non- or 
incompletely penetrant alleles of PKD1 inherited at a homozygous state, or in trans with another 
mutation4, 5. 
In kidneys the primary defect has been found to occur in the epithelium. A balanced expression 
level of the PKD1 and 2 genes, encoding polycystin 1 and 2 (PC1and PC2) is critical to maintain 
renal epithelial architecture. Both PC1 and PC2 are expressed in several sub-cellular compartments 
such as the primary cilium, cell-cell contacts and cell-extracellular matrix contacts. They form 
different multimeric protein complexes in the cell, modulating several signaling pathways, which 
in concert control essential cellular functions such as proliferation, apoptosis, cell adhesion, and 
differentiation6, 7. Disruption of any of these processes can lead to cyst formation, as demonstrated 
by a variety of mouse models8-12. In this review the role of proliferation, injury and repair in 
ADPKD, as well as their different signaling pathways will be discussed, with the major focus on 
planar cell polarity (PCP) and oriented cell division (OCD).
Mechanism of disease
The renal pathogenesis of ADPKD recognizes several phases. In the initiation phase, normal 
quiescent epithelial cells become hyper-proliferative13, 14. Subsequently, a phase characterized by 
cyst growth and cyst expansion caused by proliferation of cystic epithelial cells and increased 
fluid secretion, as well as extracellular matrix synthesis, can be recognized. During this phase 
also additional signaling pathways become either activated, or dysfunctional, resulting in more 
cyst growth15. These cysts detach from the original nephrons and continue to growth as isolated 
autonomous cysts.
Later on, cysts lining epithelial cells of large cysts stop dividing and apoptotic nuclei can be 
found in these cysts16. In addition, interstitial inflammatory infiltrates become apparent resulting 










































As the material obtained from kidneys of ADPKD patients mainly allows investigation of the last 
phase of the disease, mouse models had to be developed in order to study the different stages 
of the disease.
Genetic mechanism in mice
Different Pkd1- or Pkd2-mutant mouse models have been created, which are supporting the 
genetic mechanisms mentioned above. The first support for the second hit model was provided 
by the Pkd2ws25,- model. In this model, with one null allele and one instable Pkd2 allele, somatic 
rearrangements are accelerating renal cystic disease20, while mice that are heterozygous for an 
inactivating Pkd1 or Pkd2 mutation, show only a very mild phenotype. Homozygous Pkd1- and 
Pkd2-deficient mice, however, die at about embryonic stage 15.5 or directly after birth because 
of severe cystic disease, vascular defects, and/or abnormalities of the placental labyrinth20-29. On 
the other hand, mice carrying one Pkd1 as well as one Pkd2 mutant allele are viable and show 
accelerated renal cystic disease compared to the single gene phenotypes29.
Also hypomorphic mouse models for polycystic kidney disease that express Pkd1 or Pkd2 at a 
reduced level are viable, although they develop severe PKD30-32. Extra-renal manifestations such 
as cysts in liver and pancreas21-23, 28, 33-35, and aortic dissecting aneurysms have been reported 
as well30, 36. However, the severity of the phenotype and lifespan is dependent on the genetic 
background of the mouse strain (unpublished results). The models with expanded life span are 
especially useful for studying the later phases in PKD.
For proper renal development the levels of Pkd1 and Pkd2 gene expression are critical, since over-
expression leads to a renal cystic phenotype35, 37-39, although in one model Pkd2-overexpression 
did not cause cystic disease but renal tubulopathy40. In addition, extra-renal manifestations similar 
to those observed in patients have been described in a Pkd1 over-expression model38, and over-
expression of a truncated Pkd2 gene caused polycystic kidney disease and retinal degeneration 
in transgenic rats41. 
Inducible conditional deletion models
To overcome embryonic lethality and to study tissue specific effects of Pkd1-inactivation, 
inducible and conditional Pkd1 and Pkd2 deletion mice have been created, using the Cre-loxP 
system 42-48. These models have provided valuable information on the mechanisms involved in 
the initiation phase of cyst formation. Inducible Pkd1-deletion mice were used to analyze the 
kinetics of cyst formation upon Pkd1-gene disruption at different time-points after birth. In mice 
the progressiveness of cystogenesis depends on the age of Pkd1-gene disruption, e.g. in young 
mice the highest progression can be observed, while adult mice show a very slow phenotype43, 
45. The difference in progression of cystic renal disease correlates with the developmental status 





























































Around neonatal day 13, renal development enters its completion in mice and a critical switch 
in gene expression was observed45. Also renal epithelial cell proliferation is dramatically higher in 
neonatal compared to adult mice43. Knocking-out Pkd1 at postnatal day 4 results in progressive 
cyst formation with the major involvement of the distal nephron. At the moment of gene-
inactivation, the distal nephron is still elongating at that time, and shows many proliferating 
cells43. Interestingly, Pkd1-gene disruption in young adult mice, well beyond the above-mentioned 
developmental switch in gene transcription, leads to a disease progression rate intermediate to 
that of neonatal and adult mice, while young adults also show levels of renal epithelial cell 
proliferation between neonatal and adult mice45, 49. Therefore, proliferation in the absence of 
functional polycystins seems to be a trigger for cyst formation 49.
As proliferation seems to be an accelerating factor in cystogenesis in young Pkd1-deletion mice, 
proliferation should also provide an accelerating trigger for cyst formation in the kidneys from 
adult Pkd1-deletion mice with low renal epithelial proliferation rates at the moment of gene 
disruption. Indeed renal epithelial injury accelerates the progression of cystogenesis in adult Pkd1-
deletion mice49, 50. However, it cannot be excluded that proliferation is not the only accelerating 
factor, as epithelial regeneration probably shares (parts of) the cellular programs involved in renal 
development.
Also in non-orthologous inducible, conditional knockout models for renal cystic disease, in which 
kif3 or hnf1β is inactivated, injury accelerates the cystic phenotype51, 52. Although the mechanism 
underlying cyst formation in the hnf1β conditional knock-outs probably differs from the model in 
which kif3 was deleted. In all of these models the nephron segment that is targeted by the injury, 
and in which regeneration occurs, determines the origin of the majority of the cysts.
There are several possible answers to the question why proliferation accelerates cyst formation. 
One explanation may reside in the fact that in quiescent cells epithelial junction complexes, 
where also the polycystins can be found, are relatively stable but undergo extensive remodeling, 
when renal epithelial cells are forced to change their quiescent state into either proliferation, or 
migration53. Another possibility is that the polycystins themselves are not stable, and disappear 
from the junction complexes, but are crucial for proper (re-)establishment of adhesion complexes54, 
55. 
Altered ciliary signaling and planar cell polarity signaling 
The primary cilium is a common denominator in renal cystic diseases. This organelle harbors many 
of the proteins encoded by the genes mutated in a variety of renal cystic diseases56 i.e. genes 
mutated in Bardet-Biedl syndrome57, Meckel-Gruber syndrome58-63, nephronophthisis64, 65 or oral-
facial-digital-syndrome66.
During development the primary cilia on renal epithelial cells sense flow upon the start of urine 
production. This is accompanied by up-regulation and altered localization of the protein inversin. 
These changes result in a switch from canonical to non-canonical Wnt signaling, also known as 










































PCP is polarity within the plane of an epithelial monolayer, parallel to the basement membrane 
and perpendicular to apical-basal polarity, which represents as the (identical) spatial arrangement 
of cells or sub cellular structures of cells within an epithelial plane. The PCP pathway is the 
signaling pathway that affects planar polarization of cells.
In PKD, however, defects in PCP signaling are found, as well as increased canonical Wnt signaling49, 
68, 69. A proper balance of these pathways may be crucial for normal renal development and 
maintenance of tissue homeostasis since persistent activation of the β-catenin-mediated Wnt 
signaling itself also causes renal cyst formation in transgenic mouse models 10, 70. 
Ciliary signaling and PCP signaling are closely linked; these two pathways act bidirectional in 
regulating PCP and cilial/basal body orientation. At least for motile cilia, PCP roughly provides cues 
for the cilium since PCP dictates the orientation of the basal body, resulting in synchronization 
of the beating direction of motile cilia in specific tissues. On the other hand, orientation of cilia 
is optimized by hydrodynamic forces, i.e. flow71-73, and PCP is required for positioning/proper 
localization of cilia74. From these studies Marshall concluded that the cilia have a role in sensing 
the direction of fluid flow and by that can provide cues for planar orientation of the cilium/basal 
body75. Correspondingly, proper orientation and positioning of the basal body of non-motile 
primary cilia may also be regulated by PCP-signaling and hydrodynamic forces, although this 
remains to be confirmed. 
PCP and oriented cell division in development 
It is proposed that PCP signaling is needed during renal development in order to ensure the 
correct morphology and diameter of the nephrons. Defects in PCP signaling may therefore cause 
an increase in tubular diameter76, 77. Fischer et al. concluded that renal epithelial cells were planary 
polarized as cell division was oriented during renal development. Orientation of cell division was 
indicated by the orientation of the nuclear spindle along the longitudinal tubular axis, depicted as 
the Y-direction in the tubule shown in Figure 1A77. Therefore orientation of the nuclear spindle, 
measured by determining mitotic angle of the nuclear spindle relative to the tubular longitudinal 
axis, is now commonly used as a read out for PCP signaling. 
Using this method, misoriented cell division was observed in developing kidneys and dilated 
tubules and in cysts in two murine models for renal cystic disease51, 77. These findings are consistent 
with the concept that aberrant PCP signaling causes cyst formation. This hypothesis was further 
supported by the development of renal cysts in mice in which Fat4, a PCP component, was 
knocked-out11. In addition, in many mouse models presenting renal cysts, tubular dilation and 
cyst formation are accompanied by aberrant oriented cell division (OCD). However, these models 
are non-orthologous models for PKD in which the targeted epithelial cells lack cilia51, 78, non-
canonical Wnt-signaling is influenced by Wnt9b deficiency79 or in which cysts are formed upon 





























































Also for a Pkd1 conditional knockout model, misorientation of cell division has been reported in 
pre-cystic epithelia81. This contrasts a parallel publication, in which orientation of cell division was 
studied in a Pkd1, Pkd2 and Pkdhd1 model. Aberrant OCD could not be observed in pre-cystic 
tubules of Pkd1 and Pkd2-deletion mice. It was only observed upon dilation of the tubules82. These 
different findings between two independent studies on Pkd1 deletion mice may be explained by 
the differences in analysis methods. 
However, it is also possible that the accepted hypothesis, that misoriented cell division is the cause 
of cyst formation, is incorrect or incomplete, since a quite contrasting observation to the accepted 
hypothesis was made in the latter study. In Pkhd1del4/del4 mice, defective OCD, including out of the 
epithelial plane cell division, into the lumen was found. However, these mice failed to develop 
dilated tubules or cystic kidneys. 
Mitotic angles may deviate from the normal orientation in two directions, described by two angles: 
the first angle (a1) describes the deviation from the longitudinal tubular axis which is represented 
by Y in Figure 1A, but parallel to the epithelial plane (XY-plane) as shown in Figure 1B. The second 
angle (a2) describes the angle between the mitotic spindle axis and the basal membrane, a cell 
division in the YZ-plane as shown in Figure 1C. Thus a2 defines how much the mitotic spindle axis 
comes out of the epithelial plane. The paper of Nishio et al., studying OCD in Pkhd1 mutant and 
Pkd1 and Pkd2-deletion mice, as discussed above, is the first that (clearly) discriminated between 
these two angles. They showed that misorientation of cell division occurs in both directions, 
at least clearly shown for mildly dilated tubules in Pkd1 and Pkd2-deletion mice82. In addition, 
they suggested that cell division out of the plane of the epithelium in Pkhd1del4,del4, was probably 
corrected by a convergent extension-like movement into the epithelial plane of cells, resulting 
in an increased number of tubular circumferential cells but not in cystic kidneys82. It cannot be 
excluded however, that other factors may explain the lack of cyst formation in Pkhd1del4/del4, e.g. 
the complex processing of the Pkhd1 transcript.
Thus, misorientation of cell division includes cell divisions out of the plane of the epithelium. Not 
in every model misoriented cell division can be designated as the cause of cyst formation, since 
cytogenesis can develop without loss of OCD. In addition, aberrant orientation of cell division 
alone seems not to be sufficient for cyst formation and rather seems to be a permissive condition 
or an accelerating factor for tubular dilatation. 
It cannot be excluded, however, that cyst formation and renal cystic disease in the commonest 
and more adult-onset form of polycystic disease, ADPKD, are mechanistically different from 











































PCP and oriented cell division in renal epithelial regeneration 
It is likely that the complex interplay of processes involved during renal development; e.g. PCP 
signaling, OCD, convergent extension and ciliary signaling are also involved during regeneration 
of tubular epithelia. PCP signaling has already proven to be important for proper tubular epithelial 
repair80. To ensure correct tubular morphology during repair, the majority of the mitotic angles 
have to be parallel to the tubular longitudinal axis. 
Reports in which OCD was examined after injury in two different models for PKD, a Pkd1 and an 
Hnf1β deletion model, showed that the orientation of mitotic spindles during repair in controls 
is preferentially directed along the tubular (longitudinal) axis52, 81. This suggests that, like in 
developing nephrons, there is planar polarization of the epithelial cells.
As in renal development, the Pkd1 and an Hnf1β deletion model show misoriented cell division 
during regeneration52, 81. However, measurement of the mitotic angle can only be done in dividing 
cells. As the centrosomes form the spindle poles during cell division, OCD and centrosome position 
are linked78, the position of centrosomes may be used as a read-out for PCP in non-dividing 
cells. This is supported by the observation that disrupting PCP components, lead to aberrant 
positioning of the basal body/centrosome and cilium73, 74, 83, 84. Also in adult Pkd1-deletion mice 
mispositioning of the centrosome was observed during the pre-cystic phase after completion of 
repair49. These data indicate that aberrant PCP precedes cyst formation, although mispositioning 
of the centrosome was also found in tubules of adult Pkd1-deletion mice that were not subjected 
to epithelial injury, and develop cysts rather late49. 
Planar cell polarity and apical-basal polarity
OCD is accepted as a read-out for PCP as PCP-signaling regulates OCD. However, OCD is not 
regulated by the PCP pathway alone. PCP-signaling provides spatial information within the 
epithelial sheet. Other signaling pathways provide information concerning apical-basal polarity 
and regulate the direction of cell division perpendicular to the epithelial sheet, depicted as the 
Z-direction shown in Figure 1A and D (resembling asymmetric cell division known from stem-cell 
biology and neuronal development85, 86). Figure 1D shows a cell division in Y-direction, parallel 
with the plane of the epithelium, and one in the Z-direction, parallel to apical-basal polarity. 
The Par3/Par6 complex, including Cdc42 and aPKC, is required for establishing and maintaining 
polarized cortical domains in a wide variety of epithelia87-90. Thus this complex is implicated in 
apical-basal polarity and also regulates OCD91. Additionally, signaling complexes connected to 
adherens junctions, and cell-extracellular matrix contacts also provide input for the orientation 






























































Figure 1. Oriented and misoriented cell division in renal tubules. (A) Cell division within renal tubular 
epithelium is possible in three directions: in the direction of the Y-axis; parallel to the longitudinal axis of the 
tubule; in direction of the X-axis parallel to basal membrane and perpendicular to the tubular longitudinal axis 
or in the direction of the Z-axis; perpendicular to the basal membrane and the tubular longitudinal axis (B) 
Aberrant OCD with a1 describing the deviation from normal OCD in X-direction within the XY-plane (in the 
plane of the epithelium). (C) Aberrant OCD with a2 describing the deviation from normal OCD in Z-direction 
within the YZ-plane (out of the plane of the epithelium). B and C both depict axis as represented in the vertical 
tubule shown in A. (D) Correct OCD in Y-direction (left) and aberrant OCD with a deviation into Z-direction 
(right) i.e. cell division out of the epithelial plane. OCD: oriented cell division.
Signaling pathways involved in cyst expansion
A large variety of cellular changes in cyst-lining cells has been observed, and in the last decade 
it became clear that the polycystins transmit extracellular signals to the nucleus via multiple 
signaling pathways. A prominent role in cyst growth has been proposed for reduced Ca2+ influx, 
cAMP accumulation and aberrant Ras/Raf/ERK activation96, 97. Other proposed mechanisms involve 
activation of G-proteins, mTOR, PI3-kinase, Jak2-STAT1/3, NFAT (nuclear factor of activated 
T-cells), and NF-kB (nuclear factor kappa B) signaling98-100. It cannot be excluded that some of 
these pathways or second messengers, e.g. Ca2+, are involved in the early initiation steps of cyst 
formation. However, these pathways are to a large extend involved in proliferation, and thereby 
in cyst expansion. 
Tubulointerstitial fibrosis is a major process contributing to the pathology towards end-stage renal 
disease and is a feature of later stages in ADPKD disease progression. A key regulator of fibrosis is 










































nuclear translocation of the TGFβ cascade actor, SMAD2 has been detected in more progressive 
but not in early stages of the disease101. 
Recent data also indicated the involvement of the Hippo pathway in renal cystic disease. This 
pathway was first known to be important in organ and tissue size control in Drosophila. The core 
components of the Drosophila Hippo pathway are well conserved and also function as tumor 
suppressors in mammals in addition to regulating growth in terms of organ size control102. The 
Hippo signaling pathway exerts its actions in mammals by controlling the transcription of genes 
involved in proliferation and apoptosis through the transcriptional co-activator and final effector 
molecule, YAP and its ortholog TAZ.
In PKD, Hippo signaling showed altered activity103. YAP, a transcriptional co-activator and final 
effector molecule of the Hippo pathway, was observed in nuclei of dilated tubules and cyst 
in injury-induced Pkd1-deletion mice. Even more, disturbed Hippo signaling caused by, e.g. 
deregulation of YAP104, 105 or TAZ (Wwtr1) deficiency105-107, resulted in cyst formation. The observed 
altered activity of the Hippo pathway can provide a proliferative driving force for cyst expansion. 
Fascinatingly, YAP/TAZ are transcriptional co-activators for a variety of transcription factors, 
e.g. TEAD, Glis3, SMAD, ErbB4-CTF, p73, Runx2, many of them implicated in polycystic kidney 
disease69, 102, 108-110. Also it has been reported that the canonical Wnt signaling, one of the signaling 
cascades altered in cystic epithelia, is modulated by Hippo–signaling49, 68, 69, 111.
As PCP signaling provides directional information, Hippo signaling is known to control organ 
size, and possibly provides information about the number of tubular circumferential cells. In 
other words, PCP signaling tells which direction, Hippo signaling dictates how many cells in each 
direction. In order to coordinate these processes there must be crosstalk between the Hippo-
pathway and the PCP pathway. In fact, crosstalk between these pathways is possible since the 
upstream regulators of the Hippo pathway are shared with the PCP pathway; i.e. Fat, Four-jointed 
and Dachsous112. 
Although, nuclear YAP was not observed in tubular epithelial cells prior to tubular dilation and 
cyst formation103, it cannot be excluded that reduced activity of the Hippo pathway is already 
involved in the initiation of cyst formation. As mentioned above, Fat4 is in addition to a PCP 
component, also a regulator of the Hippo pathway. Therefore, it is possible that cyst formation in 
fat4-/- mice may in fact be attributed to a disbalance of Hippo and PCP signaling11.
Also in tissue regeneration the Hippo pathway is involved. Nuclear and strong cytoplasmic 
accumulation of YAP is observed during epithelial regeneration in the gut113 and a similar 
phenomenon was observed for the kidneys103. Overall these data imply that the delicate interplay 





























































Future prospects in ADPKD research
The animal models showed us the vastness and complexity of signaling pathways involved in cyst 
formation and disease progression. These pathways act in a concerted fashion as components 
of an interconnected signaling network. Experimental data also provided us, sometimes, with 
apparently conflicting results, which can mostly be explained by differences in experimental 
conditions and data interpretation. The conflicting results concerning PCP-signaling demand us 
to systematically (re-)analyze our data concerning the orientation of mitotic spindle axis. This will 
enable us to refine our hypothesis further regarding the role of PCP-signaling in the initiation of 
cyst formation, and help us dissect the role of the pathways implicated.
The complexity of the involved signaling networks suggest that it may be too ambitious and 
probably naive to think that prevention of cyst formation and delay of renal failure can be 
accomplished by targeting a single pathway. In patients cyst formation is not synchronized and 
areas with different phases of the disease can be found in the kidneys of an individual patient. 
Probably, therapy with drugs that target more than one signaling pathway will be necessary and 
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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by large fluid-filled cysts 
and progressive deterioration of renal function necessitating renal replacement therapy.
Previously we generated a tamoxifen-inducible, kidney epithelium-specific Pkd1-deletion mouse 
model and showed that inactivation of the Pkd1 gene induces rapid cyst formation in developing 
kidneys and a slow onset of disease in adult mice.
Therefore, we hypothesized that injury-induced tubular epithelial cell proliferation may accelerate 
cyst formation in the kidneys of adult Pkd1-deletion mice. 
Mice were treated with the nephrotoxicant DCVC after Pkd1-gene inactivation, which 
indeed accelerated cyst formation significantly. After the increased proliferation during tissue 
regeneration, proliferation decreased to basal levels in Pkd1-deletion mice just as in DCVC-
treated controls. However, in severe cystic kidneys, 10-14 weeks after injury, proliferation 
increased again. This biphasic response suggests that unrestricted cell proliferation after injury 
is not the underlying mechanism for cyst formation. Aberrant Planar Cell Polarity (PCP) signaling 
and increased canonical Wnt signaling are suggested to be involved in cyst formation. Indeed we 
show here that in Pkd1 conditional deletion mice expression of the PCP component Four-jointed 
(Fjx1) is decreased while its expression is required during tissue regeneration. In addition, we 
show that altered centrosome position and activation of canonical Wnt signaling are early effects 
of Pkd1-gene disruption. This suggests that additional stimuli or events are required to trigger the 
process of cyst formation. We propose that during tissue repair the integrity of the newly formed 








































































Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by progressive 
deterioration of kidney function due to the formation of fluid-filled cysts. Around the second 
decade in general only a few cysts can be detected by ultrasonography, while at middle age renal 
function declines and thousands of cysts are usually being found. ADPKD has an incidence of 1 in 
400 to 1 in 1000 in Caucasians and is in fact a systemic disease with cyst formation as the major 
hallmark. Extra-renal manifestations are hypertension, formation of aneurysms and formation of 
cysts in liver and pancreas1. In most patients ADPKD is caused by either a mutation in the PKD1 
gene, encoding the protein polycystin-1 (PC1; 85% of clinical cases), or a mutation in the PKD2 
gene, encoding polycystin-2 (PC2; 15% of clinical cases)2-4. 
The exact roles of PC1 and PC2 in cyst formation or other disease manifestations are not clear 
yet. It is known that in kidneys the primary defect occurs in the epithelium and that a balanced 
expression level of these proteins is critical to maintain renal epithelial architecture. In renal 
epithelial cells deregulated PKD1/2 gene expression, either by dose reduction or by complete gene 
inactivation through somatic mutations, initiates cystogenesis5-7. Both, PC1 and PC2 are expressed 
in several cellular compartments. The proteins form different multimeric protein complexes in 
different subcellular locations and they regulate several signaling pathways that together control 
essential cellular functions such as proliferation, apoptosis, adhesion and differentiation8, 9. As all 
these activities are highly co-coordinated, disruption of any of these processes can lead to cyst 
formation as shown by a variety of mouse models (e.g. bcl2 knock-out, c-myc over expression, 
β-catenin mutants, Fat4 knock-out)10-13.
We recently generated an inducible Pkd1-deletion mouse model in which we can induce 
Pkd1-deletion specifically in renal epithelial cells by administration of tamoxifen. These mice 
carry a tamoxifen inducible-KspCad–Cre as well as Pkd1lox2-11,del2-11 or Pkd1lox2-11,lox2-11 alleles14, 15. 
Upon administration of tamoxifen, the Pkd1-gene is deleted and renal cysts are being formed. 
Interestingly, adult mice (3-5 months) in which the deletion was induced, showed a relatively 
mild cystic phenotype after 3-5 months, while gene-disruption in newborn mice (post-natal 
day 4) resulted in massive cyst formation after 1 month. Similar data were reported for other 
models16-18. At neonatal stages kidney development is not yet completed. The kidneys might be 
more susceptible for Pkd1-gene inactivation, given the developmental switch in gene expression 
between days PN12 and 1416. In addition, cell proliferation takes place to elongate the nephron 
and therefore, we hypothesize that proliferation may accelerate cyst formation in (adult) ADPKD15. 
It has been proposed that tubular lengthening during renal development requires oriented cell 
division, which is the result of a correctly positioned orientation of the nuclear spindle axis. 
The Planar Cell Polarity (PCP) pathway controls oriented cell division and is disturbed in non-
orthologous models for PKD19, 20. This is one of the pathways mediated by Wnt signaling, since the 










































Cells can activate either the non-canonical pathway that controls PCP, or the canonical pathway 
that modulates gene expression to control cellular differentiation and proliferation. A molecular 
switch between these pathways requires the involvement of the protein inversin21.
Also tissue regeneration after injury requires massive cell proliferation and proper differentiation. 
Therefore, we studied the effects of treatment with a nephrotoxic compound on cyst formation 
and proliferation in an adult inducible Pkd1-deletion model. Indeed, renal injury accelerated cyst 
formation but did not result in unrestricted cell proliferation. Furthermore, we show that in Pkd1-
deletion mice tissue regeneration is accompanied by reduced expression of the PCP gene Four-
jointed (Fjx1), together with increased expression of targets from the canonical Wnt signaling. In 
addition, we measured a deviation of the position of centrosomes in mutant compared to control 
mice. Overall these data suggest that the integrity of the newly formed cells is altered.
Results
Rate of cyst formation correlates with cell proliferation at the time of gene disruption
We previously showed that a substantial number of proliferating Ki-67 positive renal epithelial 
cells could be observed in newborn wild-type mice, while in adult mice Ki-67 positive nuclei were 
hardly found 15. We hypothesized that the proliferation status of the tissue may contribute to the 
observed pathogenic differences between the adult and newborn tamoxifen-treated conditional 
deletion mice. In the mean time, we also generated mice with gene disruption at 5.5 weeks 
post-natal (PN40). These young-adult mice showed a more progressive phenotype compared to 
adult mice with gene disruption at 3 months, but less progressive compared to gene disruption 
at neonatal stages (not shown). Indeed, the proliferation index at 5.5 weeks is intermediate to 
newborn and adult stages: 1.5% ± 0.57 (n=6) while the mean proliferation index (PI) in kidneys 
of young mice (postnatal week 1) is 6.8% ± 1.50 (n=3) and in adult mice (>3 months) the mean 
PI is around 0.2% ±0.22 (n=3) (Fig. 1).
Renal epithelial injury accelerates cyst formation in adult conditional Pkd1-deletion mice
Tissue regeneration upon injury is accompanied by increased cell proliferation. To determine 
whether injury-induced proliferation accelerates cyst formation, adult Cre; Pkd1del2-11,lox mice 
were treated with the nephrotoxic compound 1,2-dichlorovinyl-cysteine (DCVC) (cKO+DCVC) 
or vehicle (cKO-DCVC) (22,23). As control Pkd1del2-11,wt and Pkd1del2-11,lox mice were treated with 
DCVC (control+DCVC). Blood urea (BU) concentrations were measured to monitor renal function 
and mice were sacrificed at BU levels exceeding 20 mmol/L (Fig. 2 A and supplementary Fig. S1). 








































































Figure 1. Renal epithelial cell proliferation in mice at different ages. Epithelial cell proliferation in the renal 
cortex of wild-type mice at different ages, post-natal day 7, day 40 and 3 months corresponding approximately 
to the ages at which gene disruption was induced by three days tamoxifen-treatment in conditional knock-
out mice (neonatal (PN4), young adults (PN40) and adult mice of 3 months). 
At 40hrs after treatment all DCVC treated mice showed increased BU concentrations, indicative 
for renal injury. After two weeks, BU levels were normalized to baseline. After 10-14 weeks 
blood urea levels increased again only in cKO+DCVC and all groups were sacrificed. Kidneys 
of cKO+DCVC mice showed a severe cystic phenotype (Fig. 3 C) while non-treated cKO mice 
showed only mildly dilated tubules (Fig. 3 E) and occasionally a limited area with focal cysts after 
10 to 15 weeks. The majority of cysts is from proximal tubular origin, the nephron segment that 
is most injured by DCVC treatment (Fig. 3 F)22, 23. At 2 weeks after injury only very mild tubular 
dilatation was observed in cKO+DCVC. This became more prominent at 5 weeks after injury, 
although dilatations were still mild (Fig. 3 A and 3 B respectively). 
Controls+DCVC showed no cysts or signs of tubular dilatation after 10 weeks (Fig. 3 D), or even 
after 6 months (not shown). Concomitantly, the renal cystic index was significantly increased in 
cKO+DCVC mice compared to both control groups, cKO-DCVC and controls+DCVC (Fig. 2 B). 
The kidney to bodyweight ratio (KW/BW), another marker for disease severity, is also markedly 
elevated in cKO+DCVC mice at 10-15 weeks (Fig. 2 C).











































Figure 2. Progression of PKD monitored by Blood Urea (BU) concentrations, KW/BW-ratios and cystic index. 
(A) BU concentration (mmol/L) in time for cKO+DCVC (solid lines) and cKO–DCVC (dotted lines), plotted for 
individual mice. (B) Cystic Index (%) and (C) KW/BW-ratios (%). Cystic index is presented as percentage of 
lumen in tissue. Cystic index and KW/BW-ratios are presented for individual mice with line representing the 
mean (* P<0.01; ** P<0.001).
Occurrence of severe cystic kidneys was analyzed using a Mantel-Haenszel test, with sever cystic kidneys being 
defined by a cystic index and kidney to bodyweight ratio exceeding 40% and 4% respectively. Formation of 
cystic kidneys was accelerated significantly in DCVC treated Pkd1 deletion mice compared to non-treated 
deletion mice (P<0.05).
Proliferation normalizes to base line levels after tissue regeneration in Pkd1-deletion 
mice
To study the levels of epithelial cell proliferation at different stages upon renal injury, we determined 
proliferation indexes in tubular epithelial cells of the renal cortex, the cortico-medullary region 
and the medulla, using the proliferation marker Ki-67 (Fig. 4). 
One week after injury the proliferation indexes were increased in cKO+DCVC and controls+DCVC 
compared to untreated mutants, and the levels were higher in cortex and cortico-medullary 
region in cKO+DCVC (Fig. 4 A and 4 B). After the initial repair phase, proliferation returned 
to the same level as in cKO–DCVC, reaching baseline levels at 2-5 weeks. This pattern is most 
clearly seen in the cortico-medullary region and cortex, which are mostly injured by DCVC 
treatment (Fig. 4) (22,23). In severe cystic kidneys of cKO+DCVC at 10 weeks, proliferation was 
dramatically increased again. This biphasic response, in which proliferation is increased during 
repair, but returns to basal levels before increasing again, was not observed in cKO–DCVC and 
controls+DCVC, which do not develop renal cysts at 10-14 weeks after injury.
These data suggest that cyst formation after injury is not the result of unrestricted cell proliferation 







































































Figure 3. Cyst formation in Pkd1-deletion mice. Renal sections of cKO+DCVC mice stained with PAS at (A) 2, 
(B) 5 and (C) 10 weeks after treatment. (D) At 10 weeks controls+DCVC show no signs of tubular dilation or 
cystogenesis, while (E) cKO-DCVC only show mild dilatations. (F) The first renal cysts in cKO+DCVC originate 
from proximal tubules and are positive for megalin. Cyclin D1 nuclear staining is present in cKO-DCVC (G), 
but seems more intense in cKO+DCVC (H) at 5 weeks and (I) cKO+DCVC at 10 weeks after injury. 
Figure 4. Proliferation indexes after injury in Pkd1 deletion mice. Renal sections were stained with Ki-67 and 
PI was determined in (A) cortex, (B) cortico-medullary region and (C) medulla at 1, 2, 5 and 10 weeks after 
injury. PIs in each group are presented as mean ± SD. Significant differences between cKO+DCVC (closed 
squares, solid lines) and cKO-DCVC (open triangles, dotted lines) are indicated by a, between cKO+DCVC 











































Planar cell polarity gene Fjx1 is differentially expressed upon renal injury in precystic 
Pkd1-deletion mice
Since proliferation reached baseline levels after tissue regeneration, but the DCVC-treated mutants 
form cysts much earlier than untreated mutants, we investigated whether the expression of genes 
involved in oriented cell division/planar cell polarity during tissue repair, recovery and at precystic 
and cystic stages was altered. Therefore, we studied mRNA expression of Four-jointed (Fjx1), 
Moesin (Msn) and Inscuteable (Insc) at different time-points. These genes were selected since 
they showed differential expression upon microarray analysis of cKO mice in which the Pkd1-gene 
was disrupted at post-natal day 40 (PN40). At 2 months upon gene disruption (PN40+2m), which 
is at precystic stages with mild tubular dilatations, only a limited number of genes (298/34,000; 
manuscript in preparation) was differentially expressed including Fjx1 (down-regulated), Msn (up-
regulated) and Insc (up-regulated). (Supplementary Fig. S2A). For other genes involved in PCP, 
expression was too low (Fat4, Prickle1), or did not show differential expression (Dachsous (Dchs1), 
Prickle2, Vangl and Celsr (Flamingo)). 
Importantly, expression of Fjx1 a key regulator of PCP was also reduced during the repair process 
at 1 and 2 weeks in cKO+DCVC, while expression was increased in controls+DCVC (Fig. 5 A). This 
difference persisted until 5 weeks after injury. At 10 weeks, in severe cystic kidneys, expression of 
Fjx1 was significant increased compared cKO–DCVC and control+DCVC. The expression of Insc 
en Msn was not significantly different in the different groups, although expression was slightly 
elevated at 5 weeks for Insc and significantly at 10 weeks for Insc and Msn. 
Canonical Wnt targets are differentially expressed upon renal injury in Pkd1-deletion 
mice.
Since it is expected that altered PCP is associated with increased canonical Wnt signaling, we 
analyzed mRNA expression of several canonical Wnt targets and regulators at different time-
points upon renal injury. The genes selected showed differential expression on microarrays at 
precystic stages of cKO mice with Pkd1-gene disruption at post-natal day 40. Expression of these 
genes is increased, except for Notum and Secreted Frizzled related protein 1 (Sfrp1), which show 
strongly reduced mRNA-levels (Supplementary Fig. S2B). Both genes are canonical Wnt targets 
as well as negative regulators of Wnt signaling, suggesting that they are subject to complex 
regulation24, 25. For eight other canonical Wnt targets sufficient signal was detected on the arrays 
but expression was not significantly altered (not shown).
In the DCVC-treated animals we analyzed expression of Cyclin D1 (Ccnd1), Survivin (Birc5), 
Prominin-1 (Prom-1) and Notum (Notum), which are direct canonical Wnt targets with differential 








































































Figure 5. mRNA expression of the PCP component (A) Four-jointed (Fjx1), canonical Wnt targets (B) CyclinD1 
(Ccnd1), (C) Survivin (Birc5), (D) Prominin-1 (Prom-1), (E) indirect Wnt target and Wnt regulator Secreted 
Frizzled related protein 1 (Sfrp1) and (F) Wnt regulator Glypican-3 (Gpc3) analyzed by RT MLPA. Expression 
was normalized to housekeeping genes. Results are shown as median of expression relative to the expression 
of cKO-DCVC, 1 week after treatment. Error bars represent interquartile range. 
Significant differences with P<0.05 between cKO+DCVC (closed squares, solid lines) and cKO-DCVC (open 
triangles, dotted lines) are indicated by a, between cKO+DCVC and control+DCVC (open circles, dashed lines) 
by b and between cKO-DCVC and control+DCVC by c. 
In general, expression of all these genes, except the negative regulators, peaked at 1 week 
upon DCVC. However, at precystic stages mRNA levels were higher in cKO+DCVC compared to 
controls+DCVC as shown for Cyclin D1, Survivin and Prominin-1 (Fig. 5 B-D). At 1 and 2 weeks 
the relative expression was not always significantly increased, but at 5 weeks it was. Also in cystic 
kidneys, at 10 weeks, mRNA levels were significantly elevated. 
For most genes expression was also (significantly) elevated in cKO-DCVC mice compared to 
controls+DCVC, which is in agreement with increased expression seen on the microarrays of 
PN40+2m mice. Our data indicate that Pkd1-gene disruption induces canonical Wnt signaling 
already at very early, precystic stages.
The expression pattern for Cyclin D1 mRNA was confirmed by immunohistochemical staining for 
the Cyclin D1 protein. At 1 week after DCVC treatment strong nuclear accumulation of Cyclin D1 
could be observed in many nuclei in mutants and controls (Fig. 3 G-I). After the initial increase of 










































positive nuclei could be observed (Fig. 3 H, I). This was always higher in cKO+DCVC compared to 
controls+DCVC. Also in cKO–DCVC, Cyclin D1 staining increased over time. 
The expression of the two negative regulators of Wnt signaling, Sfrp1 (Fig. 5 E) and Notum (not 
shown) was significantly lower in cKO+DCVC compared to controls with DCVC. Notum can 
cleave Glypican-3, a canonical Wnt activator and converts this proteoglycan from being a Wnt 
activator to a Wnt inhibitor. The expression of the inhibitor Notum was reduced in cKO+DCVC, 
and Glypican-3 (Gpc3; Fig. 5 F) mRNA levels were substantially elevated. 
From these data we conclude that upon Pkd1-gene disruption planar cell polarity signaling is 
altered and canonical Wnt signaling is increased. 
Pkd1-deletion affects centrosome position
Mitotic spindle orientation has been used as a read-out system for aberrant PCP in kidney 
development19, 20. In the injury model aberrant PCP signaling has to be determined after repair 
of the injured tissue but in precystic stages. However, in these adult mice cell proliferation is very 
low and only a few nuclear spindles can be observed. Since components of the primary cilia/
basal body/centrosome complex also contribute to formation of the nuclear spindles, we studied 
centrosome position in interphase cells as described by Jonassen et al26.
Centrosome position was measured in proximal tubules in the cortico-medullary region at 2 
weeks after DCVC treatment. In absence of Pkd1 the normal bias towards a neutral centrosome 
position, close to the center of the apical surface of the cell, was lost (Fig. 6). This resulted in a 
significant different distribution of angles defining centrosome position in cKO+DCVC (p<0.0001) 
and cKO-DCVC (p<0.05) compared to control+DCVC. As can be appreciated from figure 6 this 
effect is stronger in cKO+DCVC, although this did not reach statistical significance. 







































































Figure 6. Distribution of centrosome position in Pkd1-deletion mice. The position of the centrosome was 
determined by measuring the angle between a line through the centre of the nucleus perpendicular to the 
basement membrane and a line through the centrosome towards this point at the basement membrane. 
Distribution of angles in cKOs was significantly different from controls+DCVC for cKO+DCVC (p<0.001 ) and 
for cKO-DCVC (p<0.05).
Discussion
ADPKD is an adult onset disease characterized by the formation of many fluid-filled cysts in both 
kidneys with advancing age. When the level of Pkd1 or Pkd2 drops below a critical threshold 
in renal epithelial cells, either by stochastic variation or because of somatic mutations, the 
differentiation status of the cells alters resulting in increased cell proliferation, extracellular matrix 
synthesis and altered fluid transport. Previously, we showed that when we knock-out the Pkd1 
gene in newborn mice rapid formation of cysts occurs, while in adult mice there is a lag time of 
a few weeks between the moment of gene disruption and the onset of increased epithelial cell 
proliferation and cyst formation15. Therefore we hypothesized that the proliferative status of the 
renal tissue at the time of gene disruption is important for the rate at which cysts are formed after 
Pkd1 conditional deletion. In addition, a different gene expression profile in neonatal and adult 










































Our data show that Pkd1-gene disruption at 5.5 weeks post-natal (PN40) leads to a disease 
progression rate intermediate to that of neonatal and adult mice. At this stage mice show levels 
of proliferation between neonatal and adult mice and are beyond the developmental switch 
in renal gene expression (PN12-14). We also show that DCVC-induced renal epithelial injury 
significantly accelerates the progression of renal cyst formation. The majority of the cysts was 
derived from the proximal tubules at the inner cortex, which is the nephron segment that is the 
main target of injury by this nephrotoxicant22, 23. A similar result has recently been shown for 
a conditional knockout model of the ciliary transport component Kif3a, which develops more 
progressive renal cystic disease upon ischemic injury20. 
Renal epithelial injury is followed by a repair phase that includes proliferation to restore the 
tubular epithelial architecture. Importantly, in DCVC-induced Pkd1-deletion mice proliferation 
decreases to basal levels after repair at 2 and 5 weeks, similar to DCVC-induced controls. From 
this we can conclude that also in the context of the renal tissue, absence of Pkd1-expression 
does not lead to unrestrained epithelial cell proliferation. These results are corroborating previous 
reports showing that cystic epithelial cells of Pkd1 null mice do not grow in nude mice27. In Pkd1-
deletion mice cell proliferation upon renal injury showed a biphasic response, e.g. after the initial 
peak in the repair phase, renal epithelial cell proliferation increased again during cyst formation 
at 10-14 weeks.
Although cell proliferation during tissue regeneration is controlled in DCVC-treated mutants, 
these mice form cysts much earlier than untreated mutants. Similar to embryogenesis and renal 
development, tissue repair reactions require properly regulated cell proliferation to restore the 
epithelial architecture. Defects in oriented cell division were observed during tubular elongation in 
renal development in non-orthologous animal models for PKD19, 20. In addition, loss of the planar 
cell polarity (PCP) gene Fat4 leads to renal cysts formation13. Altogether, these data suggest a 
potential role for aberrant PCP or oriented cell division, two closely linked pathways to which 
function only a few mammalian genes have been assigned as yet, in cystogenesis. Here, we 
investigated whether defects in PCP during tissue regeneration could be involved in accelerated 
cyst formation as observed in adult Pkd1-deletion mice. In adult precystic kidneys the number 
of proliferating nuclei with a detectable nuclear spindle is too low to measure20. Therefore, we 
studied centrosome position as described by Jonassen et al.26, who showed that the intraflagellar 
transport protein IFT20 plays a role in controlling Wnt signaling. Furthermore, it is required for 
proper positioning of the centrosomes in nondividing cells and for correct orientation of the 
mitotic spindles in dividing cells. We analyzed the position of centrosomes after repair of injury, 
but at a precystic stage. As expected, in the majority of cells of control mice (+DCVC) centrosomes 
are positioned close to the center of the apical membrane. In mutants with and without DCVC, 
however, a significantly different pattern in distribution of centrosome position was observed. 
From these data we conclude that improper positioning of centrosomes is an early event upon 







































































provide an external cue to position the mother centrosome, thereby coordinating the plane of 
cell division of an individual cell with neighboring tubular cells. Whether the effect of Pkd1-gene 
disruption on centrosome localization is a result of polycystin-1 requirement in normal ciliary 
structure and function, or through interaction with Wnt signaling components, or both, requires 
further research. 
Altered PCP-signaling was further studied by gene expression analysis. Microarray based gene 
expression profiling in precystic kidneys of conditional Pkd1-deletion mice (PN40+2m) revealed 
differential expression of the PCP-related genes Fjx1, Insc and Msn, and expression of these genes 
was studied during tissue regeneration. Although the subcellular localization of the encoded 
proteins is probably also important, the expression pattern of Fjx1 is particularly interesting. Four-
jointed is a Golgi-associated kinase that phosphorylates the extracellular domains of Fat and 
Dachsous28. In the first week after DCVC-treatment Fjx1 mRNA levels are elevated in control mice 
suggesting that four-jointed is needed during tissue repair. In Pkd1-deletion mutants, however, 
expression of Fjx1 goes down suggesting defects in PCP signaling. 
PCP is regulated by the non-canonical Wnt pathway. So, defects in PCP signaling could be 
expected to be accompanied by an increase in canonical Wnt signaling. Indeed, microarray gene 
expression analysis showed elevated mRNA levels of canonical Wnt targets in precystic stages of 
conditional Pkd1-deletion mice. Moreover, expression of the negative Wnt regulatory genes Sfrp1 
and Notum was decreased. After renal injury most of the Wnt targets analyzed showed a similar 
biphasic response for gene expression as observed for proliferation, with higher levels in the 
precystic stage in DCVC-treated mutants than in DCVC-treated controls. Cyclin D1 expression, 
however, did not show the second increase in gene expression, e.g. mRNA levels were not higher 
in cystic kidneys than in untreated mutants. Regulation of this gene and some other Wnt targets 
is complex implicating several parallel signaling pathways with positive and negative feedback 
loops. 
Since also in untreated Pkd1-deletion mice centrosome position and expression of canonical Wnt 
targets are altered, we conclude that these are early responses to Pkd1-gene disruption. We 
speculate that these early alterations create a permissive condition for accelerating cyst formation 
and that additional factor(s) are required. Abnormal integrity of the newly formed cells, resulting 
from the absence of Pkd1 expression during repair, might be such a factor. The polycystins, 
form multimeric protein complexes at the cell membrane and function in cell–cell and cell–
matrix interactions, mechanosensation and signal transduction8, 29-32. It is likely that polycystins 
are required during repair for the proper formation of these protein complexes. Without Pkd1, 
cellular structure, geometry and cohesion will be modified. In agreement with this hypothesis 
polycystin-1/-2 levels are elevated after ischemic injury33-35. Without renal injury, gradually, cell 
renewal will result in Pkd1-deficient cells with strongly disturbed cellular integrity that are more 










































Abnormal Wnt signaling has been implicated in the pathogenesis of polycystic kidney disease; 
ciliary defects affect Wnt signaling, over-expression of Pkd1 is accompanied by nuclear localization 
of β-catenin, constitutively active β-catenin induces cyst formation12, 21, 36. Recent data also suggest 
that the C-terminal tail of PC1 may have a direct role in modulating Wnt signaling by inhibiting 
the interaction between β-catenin and the T-cell factor (TCF)37. This study also demonstrated 
activation of the canonical Wnt signaling pathway in cysts of different sizes, isolated from ADPKD 
patient tissues. Our data indicate that already at precystic stages canonical Wnt signaling is 
activated. In ADPKD, activation of canonical Wnt signaling seems to be rather subtle since we did 
not observe nuclear localization of β-catenin in Pkd1-deletion mice at any stage (data not shown) 
and as we reported previously we could not detect nuclear accumulation of non-phosphorylated 
β-catenin in cyst lining epithelium in end-stage ADPKD-kidneys38. This is different from various 
forms of cancer where core components of canonical Wnt signaling are constitutively activated, 
leading to patho-physiological levels of active β-catenin, while PC1 only seems to modulate the 
canonical Wnt pathway39. 
Formally, we can not exclude that the early changes in gene expression in our mouse model are 
without biological significance and that stronger Wnt signaling observed in advanced stages 
of PKD is the result of secondary events during cyst formation. However, Lal et al.37 suggested 
that PC1 expression is necessary to inhibit basal Wnt signaling, probably by an interaction of the 
carboxy-terminal 200 amino acids cleavage product of polycystin-1 with β-catenin.
In conclusion, nephrotoxic injury dramatically accelerates polycystic kidney disease in adult Pkd1-
deletion mice. Proliferation after injury, first decreases to basal levels, indicating that accelerated 
cyst formation is not the result of unrestricted cell proliferation. Altered centrosome position and 
activation of canonical Wnt signaling are early effects of Pkd1 gene disruption but additional 
stimuli or events are required to trigger the process of cyst formation. 
Materials & Methods
Experimental animals and study design
The inducible Pkd1-deletion mice (tam-KspCad-CreERT2;Pkd1del2-1l/lox2-11) and tamoxifen treatment 
have been described previously14, 15. The Pkd1 gene was inactivated in adult mice (approximately 
11 weeks), by oral administration of tamoxifen (5mg/day, 3 consecutive days). Renal injury was 
induced 6 days later by i.p. administration of 15 mg/kg DCVC or vehicle40(40). Cre;Pkd1del,wt, 
Pkd1del,wt and Pkd1del,lox mice all received DCVC. 
Blood samples were obtained from the tail vein at indicated time points with lithium-heparin 
coated capillary tubes (Roche Diagnostics). Blood urea concentrations were determined using 
the Reflotron Plus (Roche Diagnostics). Mice were sacrificed at previous determined time points, 
or when blood urea concentrations exceeded 20 mmol/L (indicating severe renal failure). After 







































































Recombination efficiency was determined by extension MLPA (eMLPA) analysis as recently 
described by Leonhard et al.41
Local animal experimental committee of the Leiden University Medical Center and the Commission 
Biotechnology in Animals of the Dutch Ministry of Agriculture approved the performed 
experiments. 
mRNA expression analysis
For gene expression analysis, Reverse Transcriptase Multiplex Ligation-dependent Probe 
Amplification (RT-MLPA) reactions were performed as described previously42. Briefly, kidneys of 
mice sacrificed at indicated time points were homogenized and total RNA was isolated. From an 
aliquot of 60-200 ng total RNA, cDNA was synthesized. On this cDNA two separate hybridization 
reactions were performed. 
To each sample MLPA probe mix (two oligonucleotides per probe) and SALSA MLPA buffer were 
added (MRC-Holland), and samples were incubated at 95°C for 1 min followed by incubation at 
60°C for 4 hours. Ligation of annealed oligonucleotides was performed at 54°C for 10-15 min. 
followed by ligase inactivation at 98°C for 5 min and ligation products were amplified by PCR 
using SalsaTaq (MRC-Holland) and FAM or HEX-labeled primers. The amplified samples were 
mixed with Hi-Di Formamide containing GeneScan-500 ROX size standard (Applied Biosystems), 
heated for five minutes at 95°C, and run on a 3730 DNA analyzer (Applied Biosystems). 
Data were analyzed using GeneScan analysis 3.5 and Microsoft Excel software. Expression of 
the housekeeping genes Ywhaz (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide) and Hprt (hypoxanthine phosphoribosyl transferase) served 
as reference for gene expression. 
Peak ratios of target gene and housekeeping genes were calculated and results of the different 
groups were normalized to the median of the control+DCVC mice at t= 1 wk), which has been 
set to 1. Sequences and details of probes, primers and competitors are available upon request.
Quantitative gene expression analysis for Msn was performed on a 7900HT Fast Real-Time PCR 
System (Applied Biosystems) using SYBR Green technology with 2x SybrGreen mastermix (Applied 
Biosystems) according to manufacturers’ protocol. HPRT was used as housekeeping gene. Primer 
sequences are available upon request.
(Immuno-)histological analysis
Formalin fixed, paraffin embedded kidney sections (4 µm) were analyzed using standard 
haematoxylin and eosin (HE) staining, periodic acid Schiff (PAS) staining or were used for 
immunohistochemistry. Sections were subjected to heat mediated antigen retrieval procedure 
(10mM citrate buffer pH 6.0 for anti-Ki-67, anti-cyclinD1, 10mM/1mM TRIS/EDTA pH 9.0 for 
anti-g-tubulin and anti-collagenIV). After blocking of endogenous peroxidase activity for 15 
minutes in 0.1% H2O2 in water, sections were incubated
 with primary antibodies diluted in 










































using diaminobenzidine as a chromogen and counterstained with haematoxylin, dehydrated, and 
mounted. Slides for immuno-fluorescence were mounted with vectashield containing DAPI after 
secondary antibody incubation.
Antibodies
Primary antibodies: rabbit polyclonal anti-megalin (1:500, Pathology LUMC, Leiden, the 
Netherlands43), goat polyclonal anti-uromodulin (1:500, Organon Teknika-Cappel, Turnhout, 
Belgium), rabbit polyclonal anti-aquaporin-2 (1:4000 Calbiochem, Amsterdam, The Netherlands), 
polyclonal anti-Ki-67 (1:3000, Nova Castra), rabbit monoclonal anti-cyclin D1 (1:200 clone, 92G2, 
Cell Signaling), rabbit polyclonal anti-collagen IV IgG1 (1:500, Abcam) and mouse monoclonal 
anti-g-tubulin IgG1 (1:750, clone GTU-88 Sigma-Aldrich). Secondary antibodies: anti-rabbit 
envision HRP (DakoCytomation, Glostrup, Denmark), rabbit-anti-goat HRP (1:300), goat-anti-
rabbit IgG Alexa546 and goat- anti-mouse IgG1 Alexa 488 (both 1:200, Invitrogen). 
Proliferative index (PI) 
The PI was assessed as previously described15. Briefly, the percentage of Ki-67-positive renal 
epithelial cells was determined in three segments of the kidney. Between 1600 and 2200 tubular 
epithelial nuclei per section were counted in cortex (C) and cortico-medullary junction (CM) 
and 350 to 600 per section in medulla (M). Only clearly definable nuclei with heavy/or granular 
staining were identified as Ki-67 positive. 
Morphometric Analysis
PAS stained transverse kidney sections were used for determination of cystic index. Cystic index 
was defined as the area percentage of lumen over the total image area. Three to five images were 
obtained from cortex and cortico-medullary region. For both renal areas mean cystic index was 
calculated, after which total cystic index was calculated as the mean of both areas. Areas were 
determined using Image J software (public domain software, NIH, USA).
For centrosome orientation Z-stacks were acquired using a Leica DM500B microscope with a 
Leica DM DFC 350 FX camera using Leica Application Suite 1.8.0 build1346. Analyzed images 
are maximum projections of 25-30 Z-images taken 0.24 mm apart. Centrosome positions in 
transverse sectioned proximal tubules at 2 weeks after injury were determined essentially as 
described by Jonassen et al. using Image J software26. In brief, the position of the centrosome 
was determined by measuring the angle between a line through the centre of the nucleus 
perpendicular to the basement membrane and a line through the centrosome towards this point 
at the basement membrane. Collagen IV staining was used to indicate the basement membrane 









































































Statistical comparisons between groups concerning the development of cystic kidneys within 15 
weeks were performed with the Mantel-Haenszel test in which severe cystic kidneys are defined 
by a combination of kidney- to bodyweight ratio, and renal cystic index at the indicated time 
point.
Differences between groups in cystic index, KW/BW and mRNA expression were assessed using 
one-way ANOVA. 
The Kolomogorov-Smirnov Z test was used to determine differences in angle distribution between 
groups. In addition a Mann Whitney test was performed to test whether differences between 
groups were significant.
A P-value <0.05 was considered statistically significant. 
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Supplementary Figure S2. Differential expression of planar cell polarity genes and canonical Wnt targets 
in Pkd1-deletion mice.
Heat map of (A) 3 PCP genes and of (B) 10 canonical Wnt targets showing differential expression at precystic 
stage (two months after gene disruption at PN40) compared to control mice. At this time-point 298 /34,000 
genes (Illumina Sentrix BeadChips Mouse-6_v1_1) were identified to show differential expression after 
multiple test correction. Unsupervised hierarchical clustering showed that mice grouped into tamoxifen 
treated inducible Pkd1-deletion mice and untreated mice according to similarities in expression patterns. From 
these 298 genes, the PCP-genes and Wnt targets were selected and the same clustering had been applied.
Red: increased expression, green: reduced expression.
0.0°
6.7°
Supplementary Figure S3. The position of the centrosome was determined by measuring the angle between 
a line through the centre of the nucleus perpendicular to the basement membrane and a line through the 
centrosome towards this point at the basement membrane. Collagen IV staining was used to indicate the 
basement membrane shown in red, nuclei are shown in blue and g-tubulin staining for centrosomes in green. 
Autofluorescence is also detected in the same channel as g-tubulin.
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Planar cell polarity (PCP) is the polarization of cells within the plane of an epithelial cell layer. 
PCP is important in many tissues in different processes. In the kidney, it is hypothesized to be 
important in acquiring and maintaining correct tubular diameter. Aberrant PCP has been shown 
to be involved in polycystic kidney disease. Therefore, research in this field requires a method to 
study PCP. As PCP and outward-in signaling via the cilia are interconnected, the position of the 
centrosome, the base of the cilium can be used as a read-out system for PCP. Here, we provide a 
































































Monolayers of epithelial cells exhibit, in addition to apical-basal polarity, also planar cell polarity. 
Planar cell polarity (PCP) is the coordinated polarization of cells in the plane of a tissue, thereby 
referring to asymmetries within the plane of the epithelial cell layer. PCP is required for many 
cellular processes. For example, it is thought to play an important role in acquiring and maintaining 
correct tubular morphology during renal development as well as during repair after epithelial 
injury. Aberrant PCP can cause cyst formation and is altered in polycystic kidney disease.1-5
PCP and (primary) cilia exert a mutual interaction in maintaining cellular functions.
The PCP pathway plays a role in regulating the position and orientation of cilia. However, 
when cilia orient to flow direction, orientation of cilia can also regulate PCP. Cilia consist of a 
microtubule-based axoneme covered by a specialized plasma membrane that extends from the 
cell surface into the extracellular space. The basal body/centrosome forms the base of the cilium. 
The position of the centrosome indicates the position of the cilium and deviation of the normal 
position in the apical membrane may indicate altered PCP. 
Another frequently used read-out, to study aberrant PCP is a measurement of the orientation of 
the nuclear spindle, with the aim to measure alterations in oriented cell division. This analysis can 
only be done in proliferative tissue when many dividing cells are present, to obtain a sufficient 
number of measurable cells in anaphase.
Measuring centrosome position in tissues to indicate altered PCP was first described by Jonassen 
et al.5 We modified the protocol to study centrosome localization in a model for polycystic kidney 
disease. We showed that at pre-cystic stages renal tubular epithelial cells display a significantly 
different distribution of centrosome position as compared to control mice.4 In the majority of 
renal epithelial cells of control mice, centrosomes are positioned close to the center of the apical 
membrane. In mutants, however, a significantly different pattern was observed. 
The following protocol describes the morphometric analysis of centrosome position in renal 













































1. Superfrost®Plus microscope slides.
2. Xylene
3. Ethanol, anhydrous denatured, histological grade (100% and 95% and 70%)
4. Deionized water (dH2O)
5. Buffer for heat-mediated antigen retrieval 10/1 mM TRIS/EDTA, pH 9.0. 
 To prepare 1L add 1.21 g Trizma® base (C4H11NO3) and 0.372 g EDTA  
(C10H14N2O8Na2•2H2O) to 950 ml dH2O. Adjust pH to 9.0, then adjust final volume to  
1000 ml with dH2O. Store at 4°C.
6. Phosphate buffered saline (PBS)
 To prepare 1L 10X stock: add 80 g sodium chloride (NaCl), 2 g potassium chloride (KCl), 
14.4 g sodium phosphate, dibasic (Na2HPO4), and 2.4 g potassium phosphate, monobasic 
(KH2PO4) to 1 L dH2O. Adjust pH to 7.4. (adjust to pH 7.4 with HCl if necessary) Prepare 
working solution by dilution of one part with nine parts of water.
7. Antibody dilution buffer: 1% (w/v) bovine serum albumin (BSA) fraction V in PBS.
8. Normal goat serum (NGS).
9.  Primary antibody: rabbit polyclonal anti-collagen IV IgG (Abcam)
10.  Primary antibody: mouse monoclonal anti-g-tubulin IgG1 (clone GTU-88, Sigma-Aldrich)
11.  Secondary antibody: goat-anti-rabbit IgG Alexa546 (Invitrogen)
12.  Secondary antibody: goat-anti-mouse IgG1 Alexa 488 (Invitrogen)
13.  Vectashield containing DAPI
Image acquisition and morphometric analysis
1.  Immersion oil
2.  Leica DM500B microscope with a Leica DM DFC 350 FX camera using Leica Application 
Suite 1.8.0
3. Image J software (public domain software, NIH, USA; http://rsb.info.nih.gov/ij/).
Methods
To measure the position of the centrosome, sections will be stained with g-tubulin to indicate 
the centrosome, collagen IV to indicate the basement membrane, and DAPI for the nuclei. The 
position of the centrosome is measured by the angle defined by the line through the center of the 
nucleus perpendicular to the basement membrane and a line through the centrosome toward the 































































Regarding PCP, localization of the centrosome can be affected in two directions. In renal 
tubules, centrosome position can be changed parallel to the longitudinal axis of the tubule or 
perpendicular to it. Therefore, only true longitudinal or transversal tubular cross sections should 
be measured. Otherwise, measurements will be the result of the vector of both directions. As 
deviations may occur only parallel to the longitudinal axis of the tubule or only perpendicular to 
it, one should chose to measure deviations only in one direction, or to keep measurements for 
the two directions separate. Pooling data of measurements in two directions could result in a loss 
of information. When deviations in the longitudinal direction are considered, it is important to 
keep track of the orientation of the tubules in such a way that for all pictures it is clear what is 
the proximal and what is the distal side. 
Here, we only considered deviations in of centrosome position perpendicular to the tubular axis.
Figure 1. Measurement of centrosome position in renal tubular epithelial cells. Kidney cortex section stained 
for g-tubulin (green), type IV collagen (red), and DAPI-stained nuclei (blue). Examples of centrosomes, nuclei, 
and basal membranes are indicated by arrowheads, asterisks and arrows respectively. (A) Image of renal 
tubules with adjusted color balance. (B) The position of the centrosome was determined by measuring the 
angle between a line through the centre of the nucleus perpendicular to the basement membrane and a line 
through the centrosome toward this point at the basement membrane. Collagen IV staining was used to 
visualize the basement membranes in red, nuclei are shown in blue and g-tubulin staining for centrosomes 
in green. Autofluorescence is detected in the same channel as g-tubulin. Centrosome angles are indicated by 
a1 and a2. 
Immunofluorescence
Do not allow slides to dry at any time after step 1 during this procedure. Drying of the sections 
will result in high background staining. All incubation steps should be performed in incubation 
boxes with wetted (filter) paper on the bottom avoiding evaporation of the incubation liquid and 










































1.  Collect formalin-fixed paraffin-embedded kidney sections (4mm) on Superfrost®Plus glass 
slides and dry o/n at 37°C.
2.  Deparaffination/Rehydration
a.  Incubate sections in three washes of xylene for 5 minutes each.
b.  Incubate sections in two washes of 100% ethanol for 5 minutes each.
c.  Incubate sections in two washes of 95% ethanol for 5 minutes each.
d.  Incubate sections in two washes of 70% ethanol for 5 minutes each.
e.  Wash sections twice in dH2O for 5 minutes each. 
3.  Carefully boil slides for 10 min in 10/1 mM TRIS/EDTA using a microwave oven, and allow 
cooling down for 20 min (see Note 1 and 2)
4.  Put circles around sections using DAKO-Pen to make sure the antibody solution stays on 
the section.
5.  Preincubate with 50 ml 5% (v/v) NGS in antibody dilution buffer for 30 minutes at room 
temperature. (see Note 3)
6.  Discard blocking solution by tapping the glass slide on a tissue and wipe off the rest of the 
liquid (of course do not touch the section itself)
7.  Prepare a primary antibody mixture containing rabbit polyclonal anti-collagen IV IgG1 
diluted 1:500 and mouse monoclonal anti-g-tubulin IgG1 diluted 1:750 in antibody 
dilution buffer.
8.  Incubate with 50 ml of the primary antibody mixture o/n at 4°C with. Discard primary 
antibody solution.
9.  Rinse slides 3 times for 5 minutes with PBS. 
10.  Remove as much PBS from the glass slides as possible.
11.  Prepare secondary antibody solution: antibody dilution buffer containing goat-anti-rabbit 
IgG Alexa546 (1:200) and goat-anti-mouse IgG1 Alexa 488 (1:200). (Keep in the dark)
12.  Incubate sections with 50 ml of the secondary antibody solution for 1hr at room 
temperature. Keep the slides from now on away from light as much as possible to avoid 
loss of signal from the Alexa Dyes.
13.  Wash 3x 5 min with PBS.
14.  Remove as much of the PBS as possible with filter paper without touching the section  
and air dry the section for a few minutes.
15.  Mount slides with Vectashield containing DAPI 
Image acquisition and morphometric analysis
1.  The slides are viewed using fluorescent microscopy. Excitation at 556 nm induces 
fluorescence of the Alexa 546 dye at 573 nm (orange emission) for the collagen IV, while 
excitation at 495 nm induces fluorescence of the Alexa 488 dye at 519 nm (green emission) 
for g-tubulin, marker for centrosomes. Excitation at 345 nm induces DAPI fluorescence at 































































2.  Make Z-stacks, of 25–30 Z-images taken 0.24 mm apart, of the area in the section you are 
interested in using 63X oil-immersion lens with immersion oil. (see Note 4 and 5) 
3. Take 25-35 different pictures of the area of interest, in order to measure appropriate 
numbers of centrosome angles.
4.  Convert the Z-stack to a maximum projection. 
5.  Import images into Image J and adjust the color balance in order to make the centrosomes 
clearly visible. (Figure 1A shows an example of a maximum projection with adjusted color 
balance).
6. Enlarge the picture if needed.
7.  Select the tool for measuring angles in Image J.
8.  Measuring the angle between a line through the center of the nucleus perpendicular to 
the basement membrane and a line through the centrosome towards this point at the 
basement membrane. Collagen IV staining was used to indicate the basement membrane 
(see figure 1B). 
 
 Crl+M will put your measurement in a results screen. You can save this results file and 
open it in Excel.
 
 In Image J you have to “drag and drop” these two lines, by clicking at three points in the 
picture immediately after one another, you cannot adjust one of the two lines afterward. 
To reduce the effect of natural occurring variance and measuring errors, many angles have 
to be measured, 200-300 angles per group (3 kidneys per group). It is also wise to do a 
blind analysis.
 Only measure centrosomes which you are sure that they belong to the same cell for which 
you are drawing a line through its nucleus. (see Note 6)
9.  When analyzing measurements and performing statistics it is most clear and informative 
to look at the distribution pattern of the centrosome angles. Differences in distribution 
can be tested with the Kolomogorov–Smirnov Z-test.
Notes
1.  The antigen retrieval (AR) method is dependent on the specific antibodies, double staining 
is only possible when both antibodies give sufficient result with the same antigen retrieval 
method. Only one type of AR can be applied. We have found these antibodies to both 










































2.  First let buffer cook in microwave at high power, put slides in a rack in the buffer, and 
maintain and subboiling temperature in microwave oven (at lower power).
3.  Using a volume of 50ml is usually enough to cover the section, use more when having 
large sections.
4.  In order to get as much centrosomes in focus in one picture as possible, it is preferable to 
use a microscope that is able to make Z-stacks, followed by a maximum projection of this 
Z-stack. It is possible to use a microscope without this function, however, the amount of 
clearly visible centrosomes will be lower as they are small and not all in the same plane of 
focus.
5.  We acquired images of areas within the inner cortex of the kidney, containing transversally 
sectioned proximal tubules. You can use the collagen IV staining as well as auto-
fluorescence as a guide for the location in the kidney.
6.  If you are measuring longitudinal cross sections of tubules, make sure you know what is 
proximal and what is distal and to assign a plus or minus sign to the direction of the angle. 
Image J will not do this, it measures absolute angles.
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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by progressive 
deterioration of renal function and formation of cysts, and is an important cause of end stage 
renal disease. Previously we showed that tubular epithelial injury accelerates cyst formation in 
inducible Pkd1-deletion mice. In these mice expression of the Planar Cell Polarity (PCP) component 
Four-jointed (Fjx1) is decreased during epithelial repair, while in control mice Fjx1-expression 
is increased and may be required during tissue regeneration. In cystic kidneys, however, Fjx1 
expression is also increased. 
Besides a PCP component, Four-jointed is also implicated in the Hippo-signaling pathway. This 
pathway is involved in organ size control by regulating proliferation and apoptosis. The role of 
Hippo signaling, together with the opposing expression pattern of Fjx1 during epithelial repair 
and at cystic stages, triggered us to investigate the activity of the Hippo pathway during these 
processes. Therefore, we examined its final effector molecule, the transcriptional co-activator Yes-
associated protein (YAP) and observed that during tissue repair, YAP expression was not different 
between Pkd1-deletion mice and controls, i.e. during tissue regeneration YAP expression was 
increased and predominantly localized in the cytoplasm but normalized after tissue repair. At 
a later stage however, in cystic epithelia and epithelia of dilated tubules, strong nuclear YAP 
accumulation was observed, accompanied by up-regulation of the YAP transcriptional targets 
Birc-3, Ctgf, InhbA and Fjx1. Altered activity of the Hippo pathway was confirmed in renal tissues 
from human ADPKD and ARPKD patients, as well as in cystic renal tumors. Our data strengthen 
the concept that during epithelial repair Four-jointed is involved in PCP signaling, while in cystic 






















































ADPKD is a systemic disease with cystogenesis as its major hallmark. Extra-renal manifestations 
are hypertension, cerebral aneurysms, and cysts in liver and pancreas.1 In young adults only a few 
cysts can be detected ultrasonographically, whereas at middle age renal function declines and 
almost all normal renal parenchyma has been replaced by thousands of cysts and fibrotic tissue. 
In most patients, ADPKD is caused by either a mutation in the PKD1 gene, encoding the protein 
polycystin-1 (PC1), or a mutation in the PKD2 gene, encoding polycystin-2 (PC2).2-4 It is known 
that, in kidneys, the primary defect occurs in the epithelium and that a balanced expression 
level of these proteins is critical to maintain renal epithelial architecture. In renal epithelial cells 
deregulated PKD1/2-gene expression either by gene dose reduction, or by complete gene 
inactivation through somatic mutations, initiates cystogenesis.5-7 Both PC1 and PC2 are expressed 
in several cellular compartments and form different multimeric protein complexes, in which they 
modulate several signaling pathways that in concert, control essential cellular functions such as 
proliferation, apoptosis, cell adhesion and differentiation.8, 9 Disruption of any of these processes 
can lead to cyst formation, as demonstrated by a variety of mouse models.10-14 Previously we 
generated an inducible Pkd1-deletion mouse model in which renal epithelial specific Pkd1 
deletion can be induced by the administration of tamoxifen. Recently we showed that tubular 
epithelial injury accelerates cyst formation in the adult induced Pkd1-deletion mice. This was not 
the result of uncontrolled cell proliferation, but probably due to altered integrity of the newly 
formed cells, rendering them more susceptible for cyst formation.15 In that study we also showed 
that aberrant canonical Wnt and planar cell polarity (PCP) signaling as well are early changes after 
Pkd1 deletion. During the repair phase of tubular epithelial injury, when PCP signaling is needed, 
renal mRNA expression of the PCP-pathway component Four-jointed (Fjx1), was increased in 
controls, but not in kidneys of the Pkd1-deletion mice. Here, the expression of Fjx1 decreased 
after Pkd1-gene disruption and persisted at relatively low levels at pre-cystic stages. However, 
later on, in cystic kidneys Fjx1 expression dramatically increased. 
It has previously been shown that Fjx1 is not only involved in PCP signaling but is also a regulator 
of the Hippo pathway, via a complex and currently not completely understood mechanism.16 The 
Hippo pathway has extensively been studied in Drosophila, where it is involved in controlling 
cell proliferation and apoptosis.17-19 In addition, an important role for the Hippo pathway has 
been suggested in the regulation of organ and tissue size control. Hippo pathway mutants 
show dramatic alterations in e.g. wing size.17-20 The pathway is named after the core pathway 
component, the kinase Hippo. Via several phosphorylation steps eventually, the non-DNA binding 
transcriptional co-activator Yorkie (Yki) is phosphorylated and retained in the cytoplasm. This 
prevents Yki target genes from being transcribed. The core components of the Drosophila Hippo 
pathway are well conserved and also function as tumor suppressors in mammals in addition to 










































The abovementioned functions of the Hippo pathway, and the increased expression of Fjx1 in 
cystic kidneys, led us to hypothesize that altered Hippo signaling might also be involved in cyst 
growth. Therefore we studied the nuclear localization of the final effector molecule of the Hippo 
pathway, the Yki mammalian ortholog YAP, as well as expression of its down-stream target genes. 
We show that cysts display strong nuclear staining for YAP, while it is absent in pre-cystic tubules. 
We also show that the expression of a number of suspected mammalian YAP targets is up-
regulated in cystic kidneys of Pkd1-mutant mouse models. During tissue-repair and at pre-cystic 
stages, however, Hippo-signaling was not differentially activated in Pkd1-mutants although Fjx1 
expression was reduced. In addition, we provide evidence that activation of the Hippo pathway is 
altered during cyst growth in human ADPKD and autosomal recessive polycystic kidney disease, 
ARPKD, as well as in cyst growth in renal cancer. Our data suggest a role for aberrant Hippo 
signaling as a mechanism for cyst growth in polycystic kidney disease.
Materials and Methods
Mice
The inducible conditional Pkd1-deletion (cKO) mice (tam-KspCad-CreERT2;Pkd1del2-1l/lox2-11) and 
tamoxifen treatment have been described previously. 22, 23 For the injury experiments, cKO mice 
with gene disruption at adult age (3 months) and controls were used. Renal tubular epithelial 
injury was induced using 15mg/kg 1,2-dichlorovinyl-cysteine (DCVC) i.p.15 Cre;Pkd1del2-11,lox mice 
were treated with DCVC (cKO+DCVC) or vehicle (cKO-DCVC); as controls, Pkd1del2-11,wt and 
Pkd1del2-11,lox mice were treated with DCVC (control+DCVC). 
In the PN40 series of cKO mice, the Pkd1 gene was disrupted by tamoxifen administration 
at 3 consecutive days around day 40. Animals were sacrificed at 1, 2, 3 and 4 months upon 
tamoxifen treatment. Tissues were used for DNA- and mRNA-isolation or formalin-fixed for 
immunohistochemistry. Recombination efficiency was determined by eMLPA analysis according 
to Leonhard et al.24
The hypomorphic mouse model was described earlier by our group. 6 Mice were on a C57BL/6J 
genetic background. Control and cystic kidneys were isolated from 3-4 week old mice. 
The local ethical animal experimental committee of the Leiden University Medical Center (LUMC) 
and the Commission Biotechnology in Animals of the Dutch Ministry of Agriculture approved the 
experiments performed.
Human Tissue Samples of Normal, Cystic Kidneys and Renal Tumors
Renal tissues from ADPKD patients with end stage renal failure and controls were fixed in 40mM 
phosphate buffered 4% formaldehyde at room temperature for at least 24 hours, dehydrated 





















































transplantation, but found not suitable for technical reasons. In addition normal appearing areas 
in renal tissue from renal tumor patients were evaluated. In total 4 control samples, 5 ADPKD 
kidneys (4 with known mutations in, or positive linkage to, PKD1), 2 fetal ARPKD kidneys and 5 
patients with renal cancer were analyzed. Two were diagnosed with clear cell renal cell carcinoma 
(CCRCC), 2 with papillary renal cell carcinoma (PRCC) and 1 with renal mixed epithelial stromal 
tumor (MEST).25 All human tissue samples were obtained following procedures approved by the 
LUMC medical ethical committee (institutional review board).
Immunohistochemistry 
Formalin-fixed, paraffin-embedded kidney sections (4 µm) were stained with rabbit-anti-YAP 
antibodies (#4912, Cell Signaling, Danvers, MA, USA). Segment marker staining was performed 
on sequential sections using rabbit polyclonal anti-megalin (Pathology LUMC, Leiden, the 
Netherlands26), goat polyclonal anti-Tamm-Horsfall protein (uromodulin, Organon Teknika-
Cappel, Turnhout, Belgium), and rabbit polyclonal anti-aquaporin-2 (Calbiochem, Amsterdam, 
The Netherlands. rabbit envision HRP (Dako, Glostrup, Denmark) or rabbit-anti-goat HRP (Dako) 
were used as secondary antibodies. Immune reactions were revealed using diaminobenzidine 
and counterstained with hematoxylin. See supporting information for a more detailed protocol.
Quantification of nuclear YAP in cysts
The percentage of tubules and cysts displaying ≥50% and 25-50% YAP-positive nuclei was 
calculated in injury-induced cKO and control mice at 5 and 10 weeks after DCVC treatment. 
Therefore YAP-positive and negative nuclei in tubules and cysts in 3-4 random, non-overlapping 
fields in the renal cortex of each mouse were counted. The tubular diameter and percentage of 
YAP nuclei was determined of 10 randomly selected tubules and/or cysts in each field. 
Nuclei with strong or apparent nuclear staining were considered positive. The average tubular 
diameter in control mice was set to 1. The relative tubular diameter (RTD) was calculated for all 
tubules were divided into 4 groups; tubule (T) with a relative tubular diameter <1.25; dilated 
tubule (DT), 1.25≤ RTD <1.75; small cysts or cyst (C), 1.75≤RTD<3.5; large cyst RTD ≥ 3.5.
mRNA expression analysis
Kidneys were snap frozen in liquid nitrogen upon isolation and stored at -80°C until further 
processing. Total RNA was isolated from renal tissue homogenates using TRI-Reagent (Sigma-
Aldrich, St. Louis, MO, USA) according to the manufacturers’ protocol. cDNA was synthesized 
with Superscript III (Invitrogen, Paisley, UK). Quantitative gene expression analysis of Birc-3, Ctgf, 
InhbA and Yap was performed on a Light Cycler 480 (Roche Applied Science, Penzberg, Germany) 
using 2x Sybr-Green master (ROX) (Roche Applied Science) according to manufacturers’ protocol. 
Data were analyzed according to the Pfaffl-method, taking PCR efficiencies into account.27 The 










































hypomorphic mouse model was set to 1 and expression was normalized to Hprt expression. 
Expression of Fjx1 was determined as previously described. 15 The detailed protocol can be found 
in the supporting information.
Statistical analysis
Statistical comparisons between groups concerning the expression of YAP targets were performed 
using one-way ANOVA with Bonferroni post-testing for cKO mice and controls. For B6 Pkd1nl,nl 
mice and controls, an unpaired t-test or an unpaired Welch’s corrected t-test in case of unequal 
variance was used. P-values <0.05 were considered significant.
Results 
YAP expression alters during tissue-repair and cyst growth 
We previously showed that adult conditional Pkd1-deletion mice (cKO) develop cystic kidneys, 
upon treatment with the nephrotoxicant 1,2-dichlorovinyl-cysteine (DCVC) while heterozygous 
Pkd1del/+-mice or vehicle treated mice do not.15 Because of the biphasic differential expression 
pattern of Fjx1 in this model we propose a role for disturbed Hippo signaling in cyst formation. To 
validate this hypothesis, YAP expression was analyzed in renal sections of mice sacrificed at 1, 2, 
5 and 10 weeks after DCVC-induced injury. 
One week after DCVC treatment, epithelial repair is in its final phase. At this stage, increased 
cytoplasmic YAP was observed in those parts of the proximal tubules the inner cortex, that 
were most severely damaged by the DCVC, in both cKO as well as controls treated with DCVC, 
compared with vehicle treated cKOs (fig. 1A-C). The kidney cortex of vehicle treated cKOs only 
shows nuclear and cytoplasmic staining of YAP in collecting ducts and distal tubules (fig. S1 A-D). 
Collecting ducts in the medulla also show nuclear staining of YAP.
Two weeks after injury, tissue repair is completed and also the increase in cytoplasmic YAP, 
observed during epithelial repair, is no longer present, showing no differences compared to non-
injured renal tissue (fig. 1D). The same expression pattern was also observed at 5 weeks after 
injury. However, 10 weeks after injury, when kidneys of DCVC treated cKOs show many cysts 
of proximal tubular origin15 (fig. S1 F), strong nuclear accumulation of YAP is observed in cystic 
tubular epithelial cells (fig. 1E and fig. S1 E). In contrast, nuclear accumulation of YAP is only weak 
or absent in proximal tubules of vehicle treated cKO (fig. 1F) or DCVC treated controls (fig. S1 
A-D), which show no cysts (controls) or only mildly dilated tubules (vehicle treated cKO’s).
mRNA expression analysis in cystic kidneys of injury-induced cKO animals 10 weeks after injury, 
as well as 3 week old Pkd1nl,nl mice, did not show significant differences in Yap expression levels 





















































Nuclear YAP is absent in pre-cystic kidneys but accumulates in cystic epithelia of different 
Pkd1-mutant mouse models
Next we examined the YAP expression in several Pkd1-mutant mouse models. cKO mice, in which 
the Pkd1 gene was deleted from the renal epithelial cells at approximately 40 days of age, develop 
polycystic kidneys within 4 months. At 3 months dilated tubules and the first cysts derived from 
proximal tubules are observed. 4 months after the gene deletion cysts derived from all nephron 
segments are presents but the largest cyst are of proximal tubular origin. In these mice nuclear 
YAP is virtually absent in proximal tubular epithelial cells at pre-cystic stages while distal tubules 
and collecting ducts show nuclear and cytoplasmic YAP (fig. 1G), similar to wild-type animals. 
However, in cystic epithelia, strong nuclear localization of YAP was observed, although also a 
minority of the cysts was negative for nuclear YAP (fig. 1H). 
Another model, the Pkd1nl,nl mice, have reduced levels of Pkd1 in all cells and show massive cystic 
kidneys 3 weeks after birth. The majority of these cysts originate from distal tubules or collecting 
ducts.6 Also in cystic kidneys of these mice, nuclear YAP is present in cyst-lining epithelia of cysts 
derived from all segments including proximal tubules, although not in all cysts (fig. 1J-L). Age-
matched wild type mice (fig. 1I), show the same phenotype as control kidneys shown in fig. 1F 
and S1A. 
Cystic epithelia in human renal ADPKD, ARPKD and tumor tissues also show nuclear YAP
To extend the observation made in mouse models to the pathology in patients, we stained renal 
tissues from ADPKD patients and control kidneys for YAP. In a substantial number of cysts, strong 
nuclear YAP accumulation was observed in the cyst-lining cells (fig. 1M), although cysts without 
nuclear YAP were present as well. Nuclear YAP was also seen in fibroblasts in fibrotic tissue in 
cystic ADPKD renal tissue (not shown). No nuclear YAP was present in proximal tubular epithelia 
of human renal control tissues, while distal tubules and collecting ducts do show some nuclear 
YAP expression (fig. S2). 
Since nuclear translocation of YAP might be a more common mechanism in cyst formation, 
we also examined cystic kidneys from autosomal recessive polycystic kidney disease (ARPKD) 
patients, as well as cysts associated with different types of renal tumors. 
Similar to renal cysts in ADPKD, cystic epithelia in ARPKD renal tissues also show prominent 
nuclear localization of YAP (fig. 1N). However, very large cysts with extremely flattened epithelia 
do not show nuclear YAP accumulation. 
Furthermore, in cysts associated with CCRCC, PRCC and renal MEST, nuclear YAP was observed 
as well (fig. 1O and S1E-F). As in ADPKD renal tissue, nuclear YAP is also observed in fibroblasts 
in fibrotic tissue in ARPKD kidneys (fig. 1N) and renal tumors (not shown).
Staining of sequential sections with nephron segment markers, revealed that in ADPKD, ARPKD 
and renal tumor tissue most cysts already lost their marker. However, in both ADPKD and ARPKD, 










































displaying nuclear YAP, are observed. CCRCC and PRCC are derived from proximal tubular 
epithelia while cysts in renal MEST originate from proximal tubular epithelia, distal tubule and 
loop of Henle (thin segment).28-30
In summary, robust nuclear accumulation of YAP is present in cystic epithelia derived from 
different segments of the nephron in various Pkd1-mutant mouse models, but not in pre-cystic 
and in control tissues. Accumulation of nuclear YAP was also observed in human ADPKD and 
ARPKD cystic epithelia, as well as in cysts associated with renal tumors, indicating that altered 
Hippo signaling is a common feature in cyst growth.
Figure 1: YAP expression in renal tissues. A-C shows YAP expression in inducible Pkd1-deletion 
mice (cKO) 1 week after DCVC treatment; (A) cKO–DCVC, (B) cKO+DCVC and (C) control+DCVC. D 
shows cKO+DCVC 2 weeks after DCVC treatment, E and F display respectively cKO+DCVC and cKO-DCVC 10 
weeks after DCVC treatment. G and H show (G) non-cystic tubules and (H) cystic tubules in an inducible Pkd1-
deletion mouse 3 months after gene disruption (at 40 days). I shows staining for YAP in 3 week old Pkd1wt,wt 
and J-L in Pkd1 nl,nl mice. K and L stained for (I,J) YAP (K) megalin and (L) aquaporin 2. PT; proximal tubule as 
judged by anti-megalin staining, DT; distal tubule as judged by anti-Tamm Horsfall protein staining (not shown), 
CD; collecting duct as judged by anti-aquaporin 2 staining.
M, N and O show human renal tissue of (M) ADPKD, (N) ARPKD and (O) mixed epithelial and stromal renal 
tumor. Open arrowheads indicate increased cytoplasmic staining of YAP; closed arrowheads indicate examples 































































































Dilated tubules and cysts show increased numbers of nuclei with nuclear YAP 
To confirm the findings observed with immunohistochemistry described above, nuclear staining 
of YAP was quantified in the injury-induced cKO mice at 5 and 10 weeks after nephrotoxic 
injury, as this model develops cysts predominantly from proximal tubular origin. The percentage 
of tubules, dilated tubules cysts and large cysts containing >50% and 25-50% of YAP positive 
nuclei was calculated. Tubules and cysts derived from distal tubules or collecting duct, as judged 
by the cytoplasmic YAP staining, were excluded from the analysis.
Table 1 shows that 70% of the cysts from kidneys at 10 weeks after injury show ≥50% YAP-
positive nuclei where only 10% of the tubules in time-matched controls show ≥50% YAP- positive 
nuclei. The percentage of large cysts with ≥50% YAP-positive nuclei is lower than in cysts (i.e. 
58%).
In addition, the analysis revealed that in dilated tubules and tubules in cystic kidneys, the number 
of YAP positive nuclei is already increased (60% and 65% respectively) compared to tubules 
in control kidneys. However, it must be noted that these tubules, although showing a normal 
tubular diameter, show aberrant morphology, including enlargement of the tubular lumen and 
disappearance of brush border. Tubules in pre-cystic, injury-induced kidneys do not show this 
marked increase in YAP positive nuclei.
In summary, in injury-induced cKO mice morphologic aberrant tubules, dilated tubules and cysts 
show increased percentages of YAP positive nuclei. 
Table 1: Quantification of nuclear YAP in tubules and cysts of injury-induced cKO mice





control + DCVC (n=2) 5 weeks T 46 0 2
DT 1 0 0
cKO + DCVC (n=3) 5 weeks T 41 2 10
DT 37 14 8
C 2 0 100
Control +DCVC (n=3) 10 weeks T 68 10 12
DT 3 33 33
cKO +DCVC (n=3) 10 weeks T 34 65 27
DT 55 60 45
C 30 70 13
LC 12 58 17
T; tubule, <1.25 times normal tubular diameter, DT; dilated tubule, ≥1.25 < 1.75 times normal tubular diameter, 





















































Up-regulation of transcriptional targets of YAP
YAP is a transcriptional co-activator which can drive the expression of target genes. A number 
of Yki target genes have been identified in Drosophila. In mammals however, the targets of YAP 
are barely known. We investigated the expression of several “suspected” YAP targets that were 
chosen according to homology with Drosophila Yki target genes, or because of previous reports. 
We analyzed the expression of baculoviral IAP repeat-containing-3 (Birc-3; also known as cIAP-
1 and cIAP-2), inhibin beta-A (InhbA) and connective tissue growth factor (Ctgf) in the injury-
induced adult Pkd1-deletion mice and the hypomorphic Pkd1nl,nl mice. Birc-3 is the homologue of 
dIAP1, a well established Yki target. Ctgf and InhbA have been reported as YAP targets in mice.31, 
32 In cKOs, renal expression of YAP targets was not increased 2 weeks after injury (fig. 2A-C). 
Even more, Birc-3 expression is lower in vehicle treated cKOs relative to DCVC treated controls 
(fig. 2A).
In contrast, Birc-3 and InhbA show significant up-regulation only at cystic stages of injury-induced 
cKOs compared to DCVC treated controls and vehicle treated cKOs (fig. 2A). Expression of these 
genes is also markedly increased in cystic kidneys of 3-4 weeks old Pkd1nl,nl mice, as well as Ctgf 
which is not increased in cystic kidneys of DCVC treated cKOs (fig. 2C-F). 
Besides regulating the Hippo pathway, Fjx1 is also thought to be a transcriptional target of YAP.18, 
33, 34 We previously reported increased expression of Fjx1 in cystic kidneys of DCVC treated cKO 
mice.15 Also cystic kidneys of Pkd1 nl,nl mice show up-regulation of Fjx1 (data not shown).
In summary, three or four out of four “suspected” transcriptional targets of YAP were up-regulated 
in cystic kidneys of injury-induced cKO mice or hypomorphic Pkd1 mutant mice, respectively. 
Thereby further supporting Birc-3, InhbA and Fjx1 as targets of YAP, but also indicating a more 










































Figure 2: Relative expression of YAP targets in Pkd1-mutant mouse models. Expression of Birc-3, 
InhbA and Ctgf (A through C respectively) in controls treated with DCVC (white bars), and cKO animals 
treated with vehicle (grey bars) and with DCVC (black bars). Expression levels of controls+DCVC at 2 wks after 
injury have been set to 1. (D-F) Expression of the same genes in 3-4 weeks old Pkd1nl,nl mice and wild types; 
expression in wild types has been set to 1. * P< 0.05, **P<0.01, *** P<0.001
Discussion
The Hippo signaling pathway is emerging as an important pathway not only in organ size control 
but also in cancer. The product of the neurofibromatosis type II tumor suppressor gene (NF2), 
Merlin, is a regulator of the Hippo pathway. In addition, increased YAP expression and nuclear 
accumulation were shown in multiple types of human cancer. 35-38
Here, we provide for the first time evidence for altered activation of the Hippo signaling 
pathway in cyst growth in ADPKD and other cystic diseases. In mouse models for ADPKD nuclear 
localization of YAP is only observed in cystic epithelia and dilated tubules but not in pre-cystic 
tubules. Nuclear YAP was detected in cysts derived from all segments. Although normal distal 
tubules and collecting ducts already show nuclear YAP, it is very likely that the Hippo pathway is 
also affected in cysts derived from collecting ducts and distal tubules, as Pkd1nl,nl cystic kidneys 





















































Increased amounts of YAP-positive nuclei are observed in morphological aberrant tubules, dilated 
tubules and cysts but not in normal looking pre-cystic tubules. This suggests that aberrant Hippo 
signaling is not an initiating event in cyst formation but accompanies cyst growth. 
Our findings, showing altered Hippo signaling during cyst growth, are in line with previous 
studies reporting renal cyst formation caused by disturbed Hippo signaling, e.g. deregulation of 
YAP in Zebrafish results in pro-nephric cyst formation. 39, 40 In addition, mice lacking TAZ (Wwtr1), 
the YAP ortholog, show renal cystic disease. 40-42 In one of the studies however, increased protein 
levels of polycystin-2 were reported as a result of TAZ deficiency. 40
The Hippo pathway is also reported to be involved in the control of cell size. 43 Therefore, altered 
Hippo signaling may explain the observed hypertrophy of Pkd1 knock-out cells, in addition to loss 
of control of the mTOR pathway. 44
Together with Four-jointed, the PCP proteins Fat and Dachsous not only regulate PCP, but also 
regulate the Hippo pathway through a complex and not completely understood mechanism. 
Fat4 knockout mice develop cystic kidneys and it has been postulated that disturbed PCP is the 
underlying defect.13 However, its effect on the Hippo signaling pathway and YAP/TAZ translocation 
has not been addressed yet. It also remains to be investigated whether in our model increased 
expression of Fjx1 in cystic kidneys is causing altered Hippo signaling or is the result of YAP driven 
transcription.
Nevertheless, our results further strengthen the concept that during epithelial repair Four-jointed 
is involved in PCP signaling while in cystic kidneys it is related to cyst growth. Decreased expression 
of Fjx1 is a direct effect of Pkd1 inactivation while increased Fjx1 and YAP target expression 
can be regarded as an effect of altered signaling during cyst growth, an indirect effect of Pkd1 
inactivation.
Although both under and over-expression of YAP as well as TAZ deficiency, can result in cyst 
formation, in renal cystic disease it seems to be associated with an increase in nuclear YAP as 
shown in the different mouse models for ADPKD. This is confirmed by the results in patients 
with ADPKD and ARPKD, demonstrating nuclear localization of YAP in epithelia in the majority 
of cysts. This slightly heterogeneous pattern, also observed for a variety of signal transduction 
components, may be explained by the fact that cystic epithelial cells show bursts in proliferation. 
23, 45, 46
In this study we showed that several postulated targets of YAP are up-regulated in cystic kidneys, 
which is in agreement with nuclear localization of YAP in cystic epithelia. Ctgf, however, is up-
regulated in cystic kidneys of hypomorphic Pkd1 mutant mice which show first signs of fibrosis47, 
while cystic kidneys of injury-induced cKO mice show no differential Ctgf expression. These data 
suggest that regulation of Ctgf expression is complex. 
Transcriptional regulation by YAP is complex; nuclear translocation of YAP can differentially 
affect transcriptional regulation, depending on cellular context. For example, YAP mostly inhibits 










































evidence shows that the availability of transcription factors that can bind to the co-activator YAP/
Yki is dependent on tissue, cell type and probably cellular context. 21, 49 Interestingly, YAP/TAZ are 
transcriptional co-activators for a variety of transcription factors, e.g. TEAD, Glis3, SMAD, ErbB4-
CTF, p73, Runx2, many of them implicated in polycystic kidney disease. 17, 21, 50-52 Also modulation 
of canonical Wnt-signaling, one of the signaling cascades altered in cystic epithelia, by Hippo 
signaling has been reported recently. 15, 50, 53, 54 By binding Dishevelled, cytoplasmic TAZ inhibits 
canonical Wnt signaling, while increased nuclear accumulation of TAZ results in increased nuclear 
β-catenin accumulation and induction of Wnt-target gene expression.54 
Further research, to gain insight in the binding partners of YAP in different cell types and contexts, 
is required. 
Increased nuclear YAP is not only observed in cystic epithelia in ADPKD, ARPKD but also cystic 
epithelia in different renal tumors. In these tumors, cystic epithelial expression of nuclear YAP is 
independent of the VHL status of the tumor. We also observed nuclear YAP in liver cysts derived 
from bile ducts of hypomorphic Pkd1 mutant mice (not shown). Therefore, it is tempting to 
speculate that altered Hippo signaling is a general feature in cystogenesis. 
Polycystic kidneys were elegantly called “neoplasia in disguise”. 55 Indeed many pathways involved 
in neoplastic growth are also involved in cyst formation. It is not surprising that a number of drugs 
developed for the treatment of cancer have shown to be effective in attenuating cyst growth in 
PKD-mouse models. 56-60 Since altered Hippo signaling plays a role in tumorigenesis, the search 
for inhibitors of this pathway for cancer treatment can be beneficial for the hunt in the much 
needed treatment for polycystic kidney disease. 61 The critical role for TAZ/YAP in integrating and 
modulating signals from different morphogen signaling pathways, including Wnt-, Notch- and 
TGF-β-signaling further supports the idea that targeting the Hippo pathway could be effective in 
inhibiting cyst expansion and slowing down progression towards end-stage renal failure in PKD. 
47, 53, 54 An interesting future experiment will be to explore whether in vivo absence of YAP during 
cyst growth, indeed, will attenuate cyst expansion. 
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Figure S1: Overview of mouse renal tissues. A-D show control+ DCVC mice 10 weeks after DCVC 
treatment stained for; (A) YAP, (B) megalin, (C) Tamm-Horsfall protein and (D) aquaporin 2. E and F display 
an cKO+DCVC 10 weeks after DCVC treatment stained for (E) YAP and (F) megalin. G shows Pkd1-deletion 
mice 3 months after gene disruption at 40 days, stained for YAP, H shows 3 week old Pkd1 nl,nl mice, stained 
for YAP. 
PT; proximal tubule as judged by anti-megalin staining, DT; distal tubule as judged by anti-Tamm Horsfall 
protein staining, CD; collecting duct as judged by anti-aquaporin 2 staining. MEG; megalin, THP; Tamm-





















































































Overview human control, AQP2 
10x 
Overview human control, THP 
10x 
Overview human control, MEG 
10x 




Figure S2: Overview of human renal control tissues. Normal renal tissue; area without irregularities 
obtained from patient with renal mixed epithelial and stromal tumor, stained for; (A) YAP, (B) megalin and (C) 
Tamm-Horsfall protein and (D) aquaporin 2. MEG; megalin, THP; Tamm-Horsfall protein, AQP2; aquaporin 
2. PT; proximal tubule as judged by anti-megalin staining, DT; distal tubule as judged by anti-Tamm Horsfall 










































ARPKD cyst, MEG 20x 
ADPKD cyst, MEG 20x 
ARPKD cyst, YAP 20x 
ADPKD cyst, YAP 20x 












Figure S3: Cysts in human renal tissues. A and B show a cyst in ADPKD renal tissue sequentially stained 
for (A) YAP and (B) megalin. C and D show a cyst in ARPKD renal tissue sequentially stained for (C) YAP and 
(D) megalin. E and F show a cyst stained for YAP in a (E) papillary renal cell carcinoma (PRCC) and a (F) clear 
cell renal cell carcinoma (CCRCC) respectively. MEG; megalin, THP; Tamm-Horsfall protein, AQP2; aquaporin 























































Kidneys were snap frozen in liquid nitrogen upon isolation and stored at -80°C until further 
processing. Renal tissues were homogenized in PBS containing 1% 2-mercapto-ethanol using a 
MagNa Lyser Instrument (Roche). Total RNA was isolated from renal tissue homogenates using 
TRI-Reagent (Sigma-Aldrich) according to the manufacturers’ protocol. cDNA was synthesized 
with Superscript III (Invitrogen). Quantitative gene expression analysis of Birc-3, Ctgf, InhbA and 
Yap was performed on a Light Cycler 480 (Roche Applied Science) using 2x Sybr-Green master 
(ROX) (Roche Applied Science) according to manufacturers’ protocol. Primer sequences are given 
in table S1. Hprt was used as a housekeeping gene. Data were analyzed according to the Pfaffl-
method, taking PCR efficiencies into account (Pfaffl,M.W. Nucleic Acids Res. 29, e45 (2001). 
Expression was calculated relative to the median of control+DCVC at 2 wks after DCVC treatment 
or wild types in case of the hypomorphic 
mouse model, and normalized to Hprt expression. Expression of Fjx1 was determined as previously 
described (H.Happé et.al. Hum. Mol. Genet. 18, 2532-2542 (2009).  
Table S1: Primer sequences for real-time PCR 














Formalin-fixed, paraffin-embedded kidney sections (4 µm) were used. For YAP staining sections 
subjected to heat-mediated antigen retrieval procedure (10 mM citrate buffer, pH 6.0). After 
blocking of endogenous peroxidase activity for 20 min in 0.1% H2O2 in water, sections were 
pre- incubated for 1 hour with 5% normal goat serum. Subsequently sections were incubated 
over night with rabbit-anti-YAP (#4912, Cell Signaling) diluted 1:50 in 1% BSA in PBS. Segment 
marker staining was performed on sequential sections of injury-induced cKO and control mice 
at 10 weeks, of 3 weeks old Pkd1nl,nl and wild type mice, and on human renal ADPKD, ARPKD 
and tumor tissues. To this end rabbit polyclonal anti-megalin (1:500 1h at room temperature, 
Pathology LUMC, Leiden, the Netherlands (Christensen, E.I. et al. Eur. J. Cell Biol. 66, 349-364 










































Organon Teknika-Cappel, Turnhout, Belgium), and rabbit polyclonal anti-aquaporin-2 (1:4000 
o/n at 4°C, Calbiochem, Amsterdam, The Netherlands) diluted in 1% BSA in PBS were used, after 
to blocking of endogenous peroxidase activity. 
Following incubation with rabbit envision HRP (Dako) or rabbit-anti-goat HRP (1:300 Dako), 
immune reactions were revealed using diaminobenzidine as a chromogen (DAB or Liquid DAB+ 
substrate chromogen system, DAKO) and counterstained with hematoxylin, dehydrated and 
mounted.
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Autosomal dominant polycystic kidney disease is characterized by progressive cyst formation and 
fibrosis in the kidneys. 
Here we present the orthologous Pkd1nl,nl mouse model, with reduced expression of the normal 
Pkd1 transcript, on a specific genetic background, i.e. fixed 50%/50% genetic background of 
C57Bl/6 and 129Ola/Hsd (B6Ola-Pkd1nl,nl). In B6Ola-Pkd1nl,nl mice, the first cysts developed from 
mature proximal tubules around birth. Subsequently, larger cysts were visible at day 7, followed 
by distal tubule and collecting duct cyst formation and progressive cystic enlargement. These 
mice developed large cystic kidneys within 4 weeks. Interestingly, cyst expansion was followed 
by renal volume regression due to collapse of cysts. This was accompanied by focal formation of 
fibrotic areas, increased expression of genes involved in matrix remodeling and subsequently an 
increase in infiltrating immune cells. Renal function, however, remained stable over time, after 
an initial increase in blood urea within the first 4 weeks. Mice were able to survive up to a year. 
Also in kidneys of ADPKD patients collapsed cysts were observed, in addition to massive fibrosis 
and immune infiltrates. 
B6Ola-Pkd1nl,nl mice show regression of cysts and renal volume but no reduction in blood urea 
levels, implying that renal volume may not be the best predictor of progression to renal failure 





























































Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a disease characterized by the 
formation of large fluid filled cysts in both kidneys that ultimately leads to end stage renal disease 
and the requirement for renal replacement therapy at the age of 50-60 years. In addition to the 
renal pathology, extra-renal manifestations can develop, such as cysts in the liver and pancreas, 
hypertension, cardiac valvular abnormalities, and cerebral aneurysms. 1 Usually, in young adults, 
only a small number of cysts can be detected, whereas at middle age thousands of cysts 
surrounded by fibrotic tissue have replaced almost all normal renal parenchyma, leading to a 
decline in renal function.
In most ADPKD patients, one PKD1 or PKD2 allele carries a germ-line mutation while the other 
allele is normal. Renal cysts are hypothesized to develop after somatic inactivation of the ”healthy” 
allele of PKD1, or PKD2 by a ‘second hit’ mechanism. 2 In addition, haploinsufficiency, stochastic 
fluctuations in PKD1or PKD2 gene dosage below a tissue-specific threshold, may suffice to cause 
cyst formation. 3 A more complex picture was proposed in recent studies reporting several families 
with incompletely penetrant alleles of PKD1 inherited at a homozygous state, or together with an 
inactivating mutation in the other allele. 4-6
Many mouse and rat models exist for studying early phases of ADPKD, the formation and growth 
of cysts. However, few models have been described representing the phenotype observed in 
ADPKD patients with advanced stage disease characterized by cystic tissue, fibrotic areas with 
inflammation, but also regions with relative normal renal morphology. 7-9 Clearly, animal models 
closely resembling this phenotype are needed to evaluate accurately the in vivo effect of potential 
therapeutics on ADPKD disease progression in patients.
Previously, the orthologous Pkd1nl,nl mouse model with reduced expression of the normal Pkd1 
transcript, had a variable mixed genetic background. 10 These Pkd1nl,nl mice were crossed back 
to full C57BL6/J (B6) and full 129Ola/Hsd (Ola) genetic background. Here we study Pkd1nl,nl mice 
on a 50%/50% genetic background of B6 and Ola, (B6Ola-Pkd1nl,nl mice). These mice showed 
no developmental delay, in contrast to the B6-Pkd1nl,nl mice on a full B6 genetic background. 
11, 12 Here, we demonstrate that B6Ola-Pkd1nl,nl mice showed great similarities with the human 
renal phenotype regarding fibrosis and inflammation. Interestingly, B6Ola-Pkd1nl,nl mice showed 
an initial increase in renal volume, followed by a partial regression due to collapse of cysts. This 
was accompanied by the focal formation of fibrotic areas. Similar features were found in human 
kidneys with ADPKD. These observations have implications for the use of renal volume as sole 











































B6Ola-Pkd1nl,nl mice show reduced levels of Pkd1 gene expression and survive without 
growth retardation 
Pkd1nl,nl mice carry a neomycin selection cassette in intron 1, resulting in alternative splicing of 
the majority of the Pkd1 transcripts. 10 In B6Ola Pkd1nl,nl mice expression levels of the normal Pkd1 
transcript was reduced to 10% compared to 4 week old-wild-type mice (Figure S1A). Although 
expression of full length Pkd1 is strongly reduced, a 3’transcript is still produced (Figure S1B). 10
In wild-type mice normal Pkd1 expression decreased with age to 20% of the expression at 4 
weeks, while normal Pkd1 expression in mutants remained at the same low level (Figure S1A). 
Pkd2 gene expression was significantly reduced in mutants (25-30%) compared to wild-types 
at the age of 4 and 16 weeks (Figure S1C). As the tuberous sclerosis 2 (Tsc2) and Pkd1 gene 
are located tail-to-tail, Tsc2 expression was analyzed. 13 Expression in 4 week old mice was 
significantly reduced in B6Ola Pkd1nl,nl mice, while at older ages expression was not significantly 
altered (Figure S1D).
In order to determine whether hypomorphic Pkd1-mutant mice show grow retardation as 
previously reported, 10 body weight was monitored. B6Ola-Pkd1nl,nl mice, however, showed similar 
growth curves compared to wild-type littermates, both for males and females (Figure 1A, B). Only 
after 35 weeks, B6Ola-Pkd1nl,nl male mice did not increase in weight, while wild-type males still 
did. Mice could live up to 52 weeks of age, although from 24 weeks onward occasional dropout 
of mice was observed (n=3/12 before 32 weeks), and between 43 and 52 weeks 3/4 mice died 
(at 43, 48 and 50 weeks). 
Renal volume declined after 4 weeks without improvement of renal function
At different time-points mice were sacrificed and kidney-to-body weight ratios (2KW/BW) were 
determined as a measure for renal volume. Figure 1C and D show 2KW/BW and kidney weights 
respectively. 2KW/BW strongly increased during the first 4 weeks of age (12.6%) due to cystic 
expansion as shown by renal histology (Figure 1C and 2A). Strikingly, after 4 weeks 2KW/BW 
started to decline and stabilized after 12 weeks (~2.5%). This phenomenon was confirmed by 
the cystic index, showing a maximum at 4 weeks (~70%) followed by a decline (~35% at 12 
weeks; Figure 1E). 
Renal function was impaired at 4 weeks compared to 1 week, as indicated by increased blood 
urea (BU) levels (Figure 1F). However, BU levels did not decrease significantly as renal volume 




























































Figure 1. Growth curves, 2KW/BW ratios, cystic indices and blood urea levels in B6Ola-Pkd1nl,nl and 
wild-type mice. Body weight (g) for (A) males and (B) females are indicated in time (mean ± SEM, n=2-7), (C) 
total kidney weight to body weight ratio (2KW/BW) and (D) total kidney weight (g) at different ages (median 
and IQR, n=2-7 per age), (E) cystic index represented as area-percentage (median and IQR, n=2-7 per age) and 
(F) blood urea concentration in time in mmol/l (mean ± SEM, n=5-11 per age). Closed squares; B6Ola-Pkd1nl,nl 










































Cyst formation and origin of cysts 
The origin of cyst formation was evaluated at postnatal day 1, 3, 7, 14 and 28 and subsequently 
at 24 weeks, using nephron segment-specific markers (n=2-3 per age). In newborn mice, at days 
1 and 3, many dilated proximal tubules and small cysts positive for megalin were present in the 
cortex. In addition, although less numerous, dilated aquaporin-2 positive collecting ducts were 
observed (Figure S2A and C). This indicates that first the majority of cysts arise in proximal tubules 
in the cortex.
At day 7, more cysts of proximal tubular origin were found in the cortex (Figure 2J). Also the 
aquaporin-2 positive dilated collecting ducts became more numerous (Figures S2D-F). 
At day 14, epithelial cysts occupied the entire cortex and medulla which were mostly derived 
from collecting ducts (Figure 2K). Although uromodulin positive cysts were also present, many of 
these cysts showed staining for aquaporin-2 as well. Only few cysts were megalin positive (Figures 
S2G-I). In addition, normal appearing tubules were still present.
From day 14 onwards the number and size of cysts increased until 21-28 days, while only few 
normal appearing tubules were present. Four week old B6Ola-Pkd1nl,nl mice showed cysts derived 
from proximal tubules. However, the majority of cysts with marker staining were derived from 
distal tubules (or loops of Henle) and collecting ducts as indicated by staining for uromodulin and 
aquaporin-2 (Figure 2L and S2J-L). A small number of cysts were megalin positive, whereas most 
cysts showed partial, or no marker staining at all. 
At later age, when renal volume declined, cysts derived from all segments were still observed. 
For example, at 24 weeks small cysts and dilated tubules of proximal tubular origin, distal tubular 
origin/loop of Henle and originating from collecting ducts were seen. Large cysts often had lost 
expression of segmental markers. In addition, glomerular cysts could be observed from 8 weeks 
onward.
Renal volume regression is accompanied by collapsing cysts, extensive fibrosis, and 
inflammation
Histological analysis (Figure 2A) and cystic index (Figure 1E) revealed that the cysts were the 
largest at 4 weeks. Subsequently, cysts partially regressed, became fibrotic and the kidneys 
revealed relatively normal tissue (Figure 2B and C).
Although wild-type kidneys showed proliferating epithelial cells at the age of 4 weeks, the 
kidneys of B6Ola-Pkd1nl,nl mice showed significantly more proliferating cells as illustrated by the 
proliferation index (Figure 3A), i.e. multiple Ki-67 positive nuclei and stretches of positive nuclei 
were present in epithelia of dilated tubules and cysts (Figure 2Q). At 8 weeks of age, proliferation 
in wild-types was reduced and only occasional Ki-67 positive nuclei were observed. Also in B6Ola-
Pkd1nl,nl mice proliferation decreased, but remained higher than in wild-types (Figure 3A). From 
16 weeks onward (Figure 3A) proliferation seemed to increase again, which was mainly confined 




























































While apoptotic nuclei were scarce until three weeks of age, 4 and 8 weeks old B6Ola-Pkd1nl,nl 
mice showed the highest numbers as indicated by the apoptotic index, the percentage of nuclei 
positive for active caspase-3 (Figure 3B). Apoptosis was observed in cystic epithelia (Figure 2R) 
as well as in interstitial tissue and non-cystic tubules (Figure 2S). After 8 weeks, numbers of 
apoptotic nuclei in epithelia and interstitium had decreased, but still outnumbered the apoptotic 
nuclei in wild-types. From 24 weeks onward, apoptotic nuclei were abundantly present in clusters 
of inflammatory cells. At all ages, wild-type kidneys showed very limited numbers of apoptotic 
nuclei (Figure 3B).
The decrease in cystic index, and partial regression of 2KW/BW and CI, was accompanied by 
“collapse” of cysts and was paralleled by increased fibrosis as shown by SMA and Sirius red 
staining (Figure 2D to 2I). Areas with collapsed cysts were occupied with fibrotic tissue and 
remnants of collapsed cysts were visible (Figure 2P and S3A and B). Regression of renal volume 
was preceded by an increase in SMA positive cells surrounding cysts at 4 weeks (Figure 2D). 
Besides fibrosis, increased numbers of inflammatory cells were observed. Already at 4 weeks, 
small clusters of infiltrating cells were present in cystic kidneys, as indicated by CD45 staining 
(Figure 2M), while wild-type kidneys only show limited numbers of individual inflammatory cells. 
In time, in cystic kidneys, these clusters became more numerous and larger (Figure 2N and O), 
sometimes filling the lumen of the remnant structure of a cyst (Figure 2C and 3A-B). 
Careful histological analysis of renal tissue of ADPKD patients also revealed regressing or collapsing 
cysts, as well as cyst remnants (Figure S3C-E), although the frequency of such abnormalities was 
relatively low.
Increased expression of genes involved in matrix remodeling in cystic kidneys
Expression of genes involved in matrix remodeling was examined using RT-MLPA (Reverse 
Transcriptase-Multiplex Ligation-dependent Probe Amplification). A key regulator of extracellular 
matrix (ECM) remodeling and the fibrotic response is Transforming Growth Factor-β (TGF-β). 
Expression of down-stream targets such as the plasminogen activator inhibitor-1 (PAI-1 encoded 
by Serpine1) as well as Mmp2, EDA-Fn and Col1a1, encoding matrix metalloproteinase-2, 
Fibronectin (EDA fragment) and collagen I, is strongly up-regulated in cystic kidneys of Pkd1nl,nl 
mice, peaking at 4 weeks when renal volume was maximal (Figure 4A-D). While expression of PAI-
1 is up-regulated, expression of its target, urokinase-type plasminogen activator (u-PA), is reduced 
(not shown). Also the mRNA level of another inhibitor in plasmin synthesis, alpha-2 anti-plasmin 
(Serpinf1), is increased as well (not shown).
In agreement with the expression data, Sirius red staining showed a large increase in ECM 
deposition from 4 to 8 weeks. After 8 weeks there was a mild increase in ECM deposition, 
but largely in new foci originating from collapsing cysts. Thus increased ECM deposition is 
accompanied by the expression of genes involved in ECM remodeling. The expression of these 





































































































B6Ola Pkd1nl,nl mice show extra renal abnormalities 
To determine whether B6Ola-Pkd1nl,nl mice develop cysts in liver and pancreas, sections of these 
organs were analyzed. All examined mice showed bile duct ectasia and/or hyperplasia from 4 
weeks onwards (n= 32/32; Figure S4), which increased with age. From 12 weeks on, a subset of 
mice (n=5/7) showed external bile duct dilation. Hepatic fibrosis appeared at 24 weeks in a subset 
of mice (n=2/5), while at 32 weeks all mice showed hepatic fibrosis (n=5/5). Pancreatic cysts were 
not observed.
In addition, aortas were isolated from mice aged between 4 and 8 weeks (n=8), and analyzed 
for the presence of aortic dissecting aneurysms that were previously reported for Pkd1nl,nl mice on 
full C57/BL/6J or mixed genetic background. 11 B6Ola-Pkd1nl,nl mice did not show dissecting aortic 
aneurisms, although in 1 out of 8 B6Ola-Pkd1nl,nl mice, segmental granulomatous chronic lesions 
were present in the arterial wall and peri-arterial regions. 
Figure 2. Histopathological characteristics of cystic kidneys in B6Ola-Pkd1nl,nl mice. (A-C) PAS 
staining showing progression of cystic disease in B6Ola-Pkd1nl,nl mice at 4, 8, and 24 weeks of age 
respectively, original magnification 2,5x. (D-F) SMA staining showing myofibroblasts and (G-I) Sirius red 
staining for collagen as markers for fibrosis at 4 (D,G), 8 (E,H) and 24 (F,I) weeks of age, original magnification 
10x. (J-L) Origin of cyst formation, showing dilated tubules and cysts of proximal tubular origin at D7 as 
indicated by staining for megalin (J), cysts of collecting duct origin at D14 (K) and D28 (L) as indicated by 
staining for aquaporin-2. Original magnification 10x, 10x and 5x respectively. (M-O) Increased infiltration 
of inflammatory cells with disease progression as indicated by CD45 staining at 4, 8 and 24 weeks of age 
respectively, original magnification 10x. (P) Example of collapsing cysts at 24 weeks of age, Sirius red staining, 
original magnification 10x. (Q) Stretch of, and Ki-67 positive nuclei in cystic epithelium at 4 weeks of age. 
Original magnification 20x. (R,S) Active caspase-3 staining showing apoptotic nuclei in cystic (R) and non 
cystic epithelia (S) at 4 weeks of age. Original magnification 40x. 
Asterix indicates immune infiltrate filling the lumen of the remnant structure of a cyst. Closed arrowheads 
indicate examples of positive nuclei in epithelia, while open arrowheads indicate positive nuclei in interstitium. 












































Figure 3. Proliferation index and apoptotic index in time in B6Ola-Pkd1nl,nl and wild-type mice.
(A) Proliferation index presented as percentage of Ki-67 positive nuclei over total nuclei. (B) Apoptotic index 
presented as percentage of active caspase-3 positive nuclei over total nuclei. Results are shown as mean ± 
SEM. *; P<0.05, **; P<0.01.
Gene expression of potential biomarkers 
Neutrophil gelatinase-associated lipocalin (NGAL), sulfated glycoprotein-2 (clusterin) and 
prostaglandin D2 synthase have been described as potential biomarkers to monitor disease 
progression in ADPKD. 14-17 The genes encoding for these potential biomarkers, Lcn2, Sgp2 and 
Ptgds respectively, all showed increased mRNA expression levels in B6Ola Pkd1nl,nl mice compared 
to wild-type animals, at all ages. Expression of Lcn2 and Sgp2 peaked at 4 weeks and strongly 
decreased as renal volume regressed (Figure 5 A, B), while Ptgds expression did not show such 
a strong correlation with renal volume (not shown). Also complement component 3 (C3), an 
important player in the innate immunity response, is regarded as a potential biomarker. 18 We 
found that C3 expression was highly elevated in cystic kidneys and further increased during 




























































Figure 4. Renal mRNA expression of genes involved in matrix remodeling at different ages. mRNA 
expression of (A) Serpine1 (PAI-1) (B) Mmp2, (C) Fn1(EDA) and (D) Col1a1 as analyzed by RT-MLPA. Expression 
was normalized to the housekeeping gene HPRT. Results are shown as median expression relative to the 
expression of wild-type mice at the age of 4 weeks, error bars represent interquartile range (n=2-5). Closed 
squares; B6Ola-Pkd1nl,nl mice, open diamonds; B6Ola-Pkd1wt,wt. The dotted line represents 2KW/BW, indicated 










































Figure 5. Renal mRNA expression of potential biomarkers for ADPKD disease progression at 
different ages. mRNA expression of (A) Lcn2, (B) Sgp2and (C)C3, as analyzed by RT-MLPA. Results are shown 
as median expression relative to the expression of wild-type mice at the age of 4 weeks, error bars represent 
interquartile range (n=2-5). Closed squares; B6Ola-Pkd1nl,nl mice, open diamonds; B6Ola-Pkd1wt,wt. The dotted 
line (in A and B) represents 2KW/BW, indicated on right y-axis, showing pattern of renal volume in time. 





























































The Pkd1nl/nl mouse model is an orthologous model for polycystic kidney disease. The severity of the 
phenotype varies among mice with a mixed genetic background. 10 Here we report that Pkd1nl,nl 
mice on a fixed 50%/50% genetic background of B6 and Ola, develop large cystic kidneys within 
4 weeks, but can survive up to a year. All models homozygous for a Pkd1 inactivating allele, 
present with severe cystic kidneys around E15 and do not survive embryonic development. 19-23 
In contrast, the B6Ola-Pkd1nl,nl mice, express low levels of Pkd1, are viable, and exhibit grossly 
normal kidney structure, but with dilated proximal tubules at birth. Although expression of the 
full length Pkd1 transcript was strongly reduced, a 3’-transcript is still produced and it cannot 
be excluded that this may affect renal development and survival. 24 In B6Ola-Pkd1nl,nl mice, the 
first cysts develop from mature proximal tubules around birth. Subsequently, larger cysts were 
visible at day 7, followed by distal tubule and collecting duct cyst formation and progressive 
cystic enlargement. At 3-4 weeks of age the majority of cysts were derived from distal tubules 
or collecting ducts. This is in agreement with our previous findings in 4-7 week old Pkd1nl,nl 
mice on a mixed genetic background 10 and is comparable to cyst formation in Pkd1nl,nl mice on 
full B6 genetic background (Hassane, unpublished). Furthermore, the first cysts observed during 
embryonic development of Pkd1-/- mice were derived from proximal tubules and later on from 
collecting ducts. 25 However, early cysts in Pkd1-/- mice can also be of glomerular origin, while in 
B6Ola-Pkd1nl,nl mice, those cysts were not detected earlier than at 8 weeks. This suggests that 
low expression of Pkd1 is able to delay glomerular cyst formation. Although we observe relatively 
low numbers of proximal tubular cysts, these cysts were not observed in other models with low 
Pkd1-gene expression, i.e. Pkd1L3,L3 mice and mice in which Pkd1-expression was reduced by an 
artificial microRNA. 26, 27 The use of different proximal tubular epithelium markers may explain the 
different observations. 
In B6Ola-Pkd1nl,nl mice, cysts showing expression of aquaporin-2 as well as uromodulin were 
frequently observed, indicating they may be derived from the transition between distal tubules 
and collecting ducts, e.g. connecting tubule. Also cysts without expression of any segment-
specific maker were observed, reflecting dedifferentiated epithelium, as frequently seen in human 
ADPKD tissues.
Notably, B6Ola-Pkd1nl,nl mice did not show growth retardation. This is in contrast to the severe 
growth retardation observed in Pkd1nl,nl mice on mixed genetic 10 and full B6 genetic background 
(Hassane, unpublished), as well as in Pkd1L3,L3 mice. 26 Also dissecting aortic aneurysms, as 
reported previously for B6-Pkd1nl,nl mice, 10, 11 were absent. Differential expression of genes, in 
the two genetic backgrounds, is likely to affect the phenotype, including aneurysm formation. 
Interestingly, different sensitivity for angiotensin-induced aneurysm formation was observed 
previously for the C57Bl/6 and 129 Ola strains. 28, 29 Also ADPKD patients, even in the same family, 
do not all develop vessel abnormalities, indicating that in addition to inactivation of the Pkd1 










































In time, B6Ola-Pkd1nl/nl mice showed accumulation of collagen and massive fibrosis, as seen in 
human cystic kidneys. This is accompanied by strong up-regulation of genes involved in ECM 
remodeling, including expression of SMAD2/3 targets (Mmp2, EDA-Fn, Col1a1 and Serpine1) 
downstream of the TGF-β signaling pathway. 12 Although TGF-β signaling is an important 
regulator of fibrosis and matrix remodeling, the pathway is also involved in tissue regeneration. 30 
This may explain the high expression of TGF-β targets already during stages characterized by cyst 
expansion. 
Additional signaling pathways known to be involved in ADPKD e.g. canonical Wnt and Hippo 
signaling were found to be differentially regulated in B6Ola Pkd1nl,nl mice. 31-34 Expression of the 
Wnt-target, Axin2 was increased while mRNA levels of Notum, a negative regulator of Wnt 
signaling, were decreased in cystic kidneys (Figure S5). In addition, several transcriptional targets 
of YAP were up-regulated (Figure S6) and also nuclear localization of YAP, the final effector of 
the Hippo signaling cascade, was observed in cyst lining epithelial cells, although this was less 
prominent at later ages (not shown). 
The regression of renal volume in our mouse model is a striking phenomenon that is also 
observed in ARPKD patients surviving the neonatal period. 35, 36 This regression, succeeding the 
development of massive cystic kidneys at 3-4 weeks, was accompanied by “collapse” of cysts 
that was paralleled by an increase in fibrosis. Collapsing cysts were also observed in human 
kidneys from ADPKD patients, but with a low frequency. Previously, it was already suggested 
that apoptosis plays an important role in the pathogenesis of PKD. Apoptosis was found to be 
abundantly present in cystic as well as non-cystic epithelia in polycystic kidneys of PKD mice 
and patients and was suggested to contribute to the loss of normal renal tubules. 37 However, 
conditional Pkd1-deletion mice do not show a significant increase in apoptosis. 38, 39 In the B6Ola-
Pkd1nl,nl mice, apoptosis in cystic epithelia was highest during the period of regression in renal 
volume, while proliferation markedly decreased. This suggests that apoptosis may not be involved 
in the formation of cysts, but may play an important role in the progression of the disease and the 
progressive deterioration of renal function.
Renal volume as clinical end-point used in clinical trials for ADPKD 40, 41 was questioned after 
disappointing results of clinical trials with mTOR inhibitors. It was suggested that renal volume 
might not be an ideal end-point in advanced PKD. 42, 43 Indeed we only observed a minor effect 
on renal volume after low dose sirolimus treatment in the B6Ola-Pkd1nl,nl model. 44 In line with 
our data, regarding renal volume regression, and increased fibrosis and inflammatory infiltrates, 
another study revealed that the extent of fibrosis and inflammation correlates better with disease 
progression to renal failure than renal volume. 45
Models, in which almost all nephrons develop cysts simultaneously in a relative short time span, 
are useful to study cyst initiation and progression. However, models closely resembling advanced 





























































Recently, several families have been reported with non- or incompletely penetrant alleles of PKD1 
or PKD2. 4-6 When these hypomorphic alleles are inherited at a homozygous state, or in trans with 
another mutation, they can cause severe, early onset PKD. Even more, two hypomorphic PKD1- 
or PKD2-alleles were identified in patients with an ARPKD-like renal cystic phenotype in families 
with no history of PKD. 5, 6
With regard to the characteristic aspects of human ADPKD disease progression, fibrosis 
and inflammation, 7 the B6Ola-Pkd1nl,nl model shows similarity with the human ADPKD renal 
pathology. But when onset and proportion of nephrons involved, is taken into account, the model 
particularly resembles patients with two incomplete penetrant alleles of PKD1 or PKD2.
In conclusion, the renal cystic phenotype of B6Ola-Pkd1nl/nl mice seems to reflect the phenotype 
of patients with early onset PKD as result of two hypomorphic mutations. This model shows 
that regression of cysts and renal volume occurs, implying that renal volume may not be a good 
predictor of progression to renal failure and end stage renal disease. 
Methods
Mice
Pkd1nl,nl mice were generated as previously described. 10 A loxP-flanked neomycin selection 
cassette was inserted into intron 1 of Pkd1 by homologous recombination and a third loxP site 
was inserted into intron 11. Chimeric offspring were backcrossed with full C57BL6/Jico (B6) 
and 129Ola/Hsd (Ola). Next Pkd1nl,nl mice on a 50%/50% genetic background of B6 and Ola, 
[(C57BL/6Jico x 129Ola/Hsd)F1=B6Ola-Pkd1nl,nl mice], were generated. Mice were sacrificed at 
several ages (n=5 B6Ola-Pkd1nl,nl, n=2 wild-types) and kidneys, liver, pancreas were isolated. From 
mice (n=8) between 4 and 8 weeks aortas were isolated.
Body weight and blood urea concentration were analyzed to monitor growth and renal function 
respectively. Blood urea concentrations were determined using the Reflotron Plus (Roche 
Diagnostics).
All experiments with mice were approved by the Animal Care and Use Committee of Leiden 
University and by the Commission for Biotechnology in Animals of the Dutch Ministry of 
Agriculture.
Human renal tissues
All human tissue samples were obtained following procedures approved by the LUMC medical 











































Formalin fixed, paraffin embedded kidney sections (4 µm) were analyzed using periodic acid 
Schiff (PAS) staining, Sirius Red staining or were used for immunohistochemistry. For staining 
with Sirius Red, de-paraffinized sections were incubated in 0.2% phosphomolybdic acid hydrate 
for five minutes and 0.1% Sirius red for 90 minutes. Subsequently sections were incubated for 
one minute in saturated picric acid and then placed in 70% ethanol, dehydrated and mounted.
Staining for segment specific markers was performed on sequential sections. Proximal tubules 
were stained using rabbit polyclonal anti-megalin (1:500 LUMC, Leiden, the Netherlands 46), 
thick ascending loop of Henle and distal convoluted tubules were stained with goat polyclonal 
anti-uromodulin protein (uromodulin, 1:500, Organon Teknika-Cappel, Turnhout, Belgium) and 
collecting ducts were stained using rabbit polyclonal anti-aquaporin-2 (1:4000, Calbiochem, 
Amsterdam, The Netherlands) 
Staining of fibroblasts was performed using mouse monoclonal anti-a-smooth muscle actin 
(SMA) alkaline phosphatase conjugate (clone 1A4, Sigma-Aldrich, St. Louis MO, USA). 
Sections were subjected to heat mediated antigen retrieval procedure (10mM citrate buffer pH 
6.0) for staining for polyclonal anti-Ki-67 (1:3000, Nova Castra, Valkenswaard, the Netherlands) 
and anti-cleaved caspase-3 (1:300, Cell Signaling, Beverly, MA). Immunohistochemistry was 
performed as described previously. 32
Acetone fixed, frozen renal sections were stained for infiltrating cells using anti-CD45 (ly5) 
antibody (clone 30-F11 01111D, Pharmingen, San Diego CA, USA) followed by incubation with 
rabbit anti-rat Ig/HRP 1:100 in PBS containing 1% normal mouse serum. Antibody complexes 
were visualized using DAB and counterstained with hematoxylin.
Formalin fixed aortas, from aortic root to the bifurcation of the iliac arteries, were sectioned and 
sections were mounted serially onto glass slides. Aortic sections were stained with hematoxylin 
eosin (HE) and resol-fuchsin staining for elastin lamellae.
Morphometric Analysis
Transverse kidney sections were stained with PAS, anti-Ki-67 and anti-active caspase-3 were 
used for determination of cystic-, proliferation- and apoptotic index respectively. Five to twelve 
random, non-overlapping, high resolution images per mouse at a magnification of 10X were 
obtained from the total renal area using a Panoramic Midi digital slide scanner (3DHistech, 
Budapest, Hungary). 
Cystic index was defined as the area percentage of lumen over the total image area. Proliferation 
and cystic index are defined by the percentage of Ki-67 and caspase-3 positive nuclei, over total 
amount of hematoxylin positive nuclei. Lumen and total area, as well as numbers positive nuclei 
were determined using Image J software (public domain software, NIH, USA).
Mean cystic, proliferation, and apoptotic index were calculated for each mouse (>3000 nuclei/





























































For gene expression analysis, Reverse Transcriptase Multiplex Ligation-dependent Probe 
Amplification (RT-MLPA) reactions were performed as described previously. 32 Per time point n=5 
B6Ola-Pkd1nl,nl mice and n=2 wt mice were analyzed.
Expression of the housekeeping gene Hprt (hypoxanthine guanine phosphoribosyl transferase) 
served as reference for gene expression. 
Peak ratios of target gene and housekeeping genes were calculated and results of B6Ola-Pkd1nl,nl 
mice were normalized to the median of 4 week old wild-type mice, which has been set to 1. Two 
Pkd1 probe sets were developed, a 5’-Pkd1 probe set, identifying exon 1-2 of the normal Pkd1 
transcript and the 3’-Pkd1 probe set identifying exon 45-46 and thereby identifying both mutant 
and normal Pkd1 transcripts. 
Sequences and details of probes, primers and competitors are available upon request. 
Statistics 
Statistical comparisons between B6Ola-Pkd1nl,nl mice and controls concerning proliferation index, 
apoptotic index and mRNA expression was performed using an unpaired t-test, or unpaired 
Welch’s corrected t-test in case of unequal variance. P-values <0.05 were considered significant.
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Figure S1: Renal mRNA expression of normal Pkd1 and TSC2 transcript in B6Ola-Pkd1nl,nl and wild 
type mice at different ages. (A) Expression of normal Pkd1-5’ transcript, (B) Pkd1-3’ transcript, (C)Pkd2 and 
(D) Tsc2. mRNA expression was analyzed by RT-MLPA. For the Pkd1 transcripts, results are shown as mean 
expression ± SEM only normalized to housekeeping genes (A and B). Pkd2 and TSC2 expression are shown 
as median expression relative to the expression of wild type mice at the age of 4 weeks, error bars represent 




























































Figure S2: Time course of cyst formation and involvement of different nephron segments. Peroxidase 
staining of renal sections from (A-C) day 1, (D-F) day 7, (G-I) day 14, (J-L) day 21 and (M-O) day 28. Sequential 
sections were stained for (A, D, G, J and M) megalin, (B, E, H, K and N) uromodulin and (C, F, I, L and O) 
aquaporin-2, indicating tubules and cysts from proximal tubular, distal tubular and collecting ductal origin 
respectively. Asterisks indicate cysts positive for two segmental markers. Arrowheads indicate cysts with 











































Figure S3: Collapsing cysts in mice and human ADPKD. Collapsing cyst in B6Ola-Pkd1nl,nl mice at the 
age of (A) 16 weeks and (B) 50 weeks and (C-E) human ADPKD. Original magnification 10x (A-D) and 5x (E). 
Figure S4: Bile duct ectasia in B6Ola-Pkd1nl,nl mice. HE staining B6Ola-Pkd1nl,nl livers at the age of (A) 8 




























































Figure S5: mRNA expression of genes involved in canonical Wnt signaling. mRNA expression of (A) 
Notum and (B) Axin2, at different ages as determined by RT-MLPA. Results are shown as median expression 
relative to the expression of wild type mice at the age of 4 weeks, error bars represent interquartile range. 
Closed squares; B6Ola-Pkd1nl,nl mice, open diamonds; B6Ola-Pkd1wt,wt. The dotted line represents KW/BW, 
indicated on right y-axis, showing pattern of renal volume in time. *; P<0.05, **; P<0.01, ***; P<0.001.
Figure S6: Expression of YAP targets. mRNA expression of YAP targets (A) Birc3, (B) Ctgf , (C) Inhba and (D) 
Fjx1 at different ages as determined by real time PCR for Birc3, Ctgf and Inhba and RT-MLPA for Fjx1. Results 
are shown as expression relative to the expression of wild type mice at the age of 4 weeks, (mean ± SEM). 




































































































































Autosomal dominant polycystic kidney disease (ADPKD) is characterized by large fluid-filled cysts 
and progressive deterioration of renal function necessitating renal replacement therapy. In this 
thesis different phases of ADPKD were studied. The major findings of this study are incorporated 
in the schematic representation of the proposed sequence of events in cystogenesis and disease 
progression shown in figure 1. The initiation phase, with hyper proliferative epithelial cells as a 
hallmark, is followed by a phase of cyst growth and cyst expansion. Later on, proliferation of 
cystic epithelia ceases and interstitial fibrosis and inflammation become apparent. 

 
          
         
   
  
 
   
Figure 1. Schematic representation of the proposed sequence of events in cystogenesis and disease 
progression in ADPKD. All tubular epithelial cells contain one mutated PKD1 or PKD2 allele and one 
unaffected allele. During life, in a subset of cells, protein levels of PC1 and/or PC2 become misbalanced due to 
a second hit or haploinsufficiency. There are early changes after inactivation of the PKD1 gene that alone are 
not sufficient for cyst formation such as up-regulation of canonical Wnt signaling and aberrant centrosome 
position (indicative of aberrant planar cell polarity).When PKD1/2-deficient cells proliferate in response to for 
example injury, cyst formation is initiated and many signaling pathways become deregulated. The epithelial 
cells become hyperproliferative and depolarized. Additional signaling pathways such as Hippo signaling 
become deregulated, thereby contributing to cyst growth and expansion. Subsequently, ECM production 
around cysts starts to occur and apoptosis is present in cystic epithelia. During the progression phase cysts 
collapse, fibrotic tissue is formed, and large immune infiltrates start to form.
Cyst initiation
In chapter 3 the initiation of cyst formation was studied. In contrast to patients with ADPKD, a 
heterozygous mutation in Pkd1 does hardly lead to cyst formation in mice. Using a tamoxifen-
inducible, kidney epithelium-specific Pkd1-deletion mouse model, our group showed that 
inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow 
onset of disease in adult mice.1 Therefore, we hypothesized that the proliferative status of the 
renal tissue at the time of gene disruption is important for the rate at which cysts are formed 










































Pkd1-gene disruption at PN40 leads to a disease progression rate intermediate to that of neonatal 
and adult mice as expected from the renal proliferation levels, which are intermediate to that of 
neonatal and adult mice. We also showed that DCVC-induced renal epithelial injury significantly 
accelerates the progression of renal cyst formation. The data in chapter 3 confirm our hypothesis 
that cyst formation after Pkd1-gene disruption is dependent on the proliferative status of the renal 
epithelial cells, as renal epithelial injury is followed by a repair phase that includes proliferation to 
restore the tubular epithelial architecture (Fig.1)
After the increased proliferation during tissue regeneration, proliferation decreased to basal levels 
in Pkd1-deletion mice just as in DCVC-treated controls. However, in severe cystic kidneys, 10–14 
weeks after injury, proliferation increased again. This biphasic response suggests that unrestricted 
cell proliferation after injury subsequent to Pkd1-gene deletion is not the underlying mechanism 
for cyst formation. 
Similar to embryogenesis and renal development, tissue repair reactions require properly regulated 
cell proliferation to restore epithelial architecture. Defects in oriented cell division were observed 
during tubular elongation in renal development in non-orthologous animal models for PKD.2, 3 
In addition, loss of the Planar Cell Polarity (PCP) gene Fat4 leads to renal cysts formation.4 
Altogether; these data suggest a potential role for aberrant PCP or oriented cell division. 
In order to investigate whether defects in PCP during tissue regeneration could be involved in 
accelerated cyst formation as in adult Pkd1-deletion mice, we analyzed the position of centrosomes 
after repair of injury at a pre-cystic stage. The use of centrosome position as a readout system for 
PCP was discussed in chapter 2 and 4. 
As expected, in the majority of cells of control mice (+DCVC), centrosomes are positioned close to 
the center of the apical membrane. In mutants with and without DCVC, however, a significantly 
different pattern in the distribution of centrosome position was observed. Centrosomes were 
positioned further away from its normal position in the center of the apical membrane above the 
middle of the nucleus. From these data, we conclude that improper positioning of centrosomes 
is an early event after Pkd1-gene disruption. Additionally, gene expression of several PCP-related 
genes was investigated and showed differential expression in pre-cystic kidneys of Pkd1 conditional 
knockout mice. The expression pattern of Four-jointed-1 (Fjx1) is particularly interesting. Our 
results suggested that Four-jointed is needed during tissue repair. In Pkd1-deletion mutants, 
however, the expression of Fjx1 decreased upon Pkd1-gene disruption, suggesting defects in PCP 
signaling. It is believed that when PCP signaling is aberrant, canonical Wnt signaling is activated.5 
Indeed signs of activated canonical Wnt signaling were observed. 
Since in untreated Pkd1-deletion mice centrosome position and the expression of canonical Wnt 
targets were also altered, we conclude that these are early responses to Pkd1-gene disruption 
(Fig. 1). We speculate that these early alterations create a permissive condition for accelerating 
cyst formation and that additional factors are required. Abnormal integrity of the newly formed 





















































that polycystins are required during repair for the proper formation of these protein complexes. 
Without Pkd1, cellular structure, geometry and cohesion will be modified (Fig. 1). In agreement 
with this hypothesis, Silberberg et al. showed that polycystins are required for assembling cell-cell 
contacts.6 Additionally, polycystin-1/-2 levels are elevated after ischemic injury.7-9 
Concurrently with the publication of our study, a report was published also showing the 
accelerating effect of injury on cyst formation in Pkd1 conditional knockout mice but without 
investigating planar cell polarity. However, in this study ischemic reperfusion injury was used 
instead of a nephrotoxic compound. Here, the cyst accelerating event is termed “third hit”, where 
the first hit is the germ line mutation in the first Pkd1 allele and the second a somatic mutation in 
the remaining “normal” allele, following the two hit hypothesis. The term “third hit”, however, 
suggests that this hit is also a genetic hit, while it is in fact a modifying factor related to tubular 
epithelial proliferation. Recently, more papers were published regarding the role PCP signaling in 
ADPKD, including a study in which cyst formation was found without aberrant PCP signaling in 
pre-cystic stages and aberrant PCP signaling but without cyst formation.10-12 
Additionally a recent paper suggested that cyst formation is more likely to be caused by non-
canonical Wnt signaling, PCP signaling, than by the related canonical Wnt signaling. Here it was 
shown that in a Pkd1 and Pkd2 model no β-catenin activity was reported after establishment of 
urinary flow or in cystic epithelia.13 How this study should be interpreted is unclear and requires 
further research, since many studies (including ours) showed that increased canonical Wnt 
signaling is associated with cyst formation. The results of all of these studies show that the 
puzzle is more complex and results and mechanisms may depend on the models used as was also 
discussed in chapter 2.
Hippo signaling and cyst growth
The Hippo signaling pathway is emerging as an important pathway, not only in organ size control 
but also in cancer. The product of the neurofibromatosis type II tumor suppressor gene (NF2), 
Merlin, is a regulator of the Hippo pathway. In addition, increased YAP expression and nuclear 
accumulation were shown in multiple types of human cancer.14-17 This pathway is subject of inves-
tigation in chapter 5, as in chapter 3 we showed that during the repair phase of tubular epithelial 
injury, when PCP signaling is needed, renal mRNA expression of the PCP-pathway component 
Four-jointed (Fjx1), was increased in controls, but not in kidneys of the Pkd1-deletion mice. Here, 
the expression of Fjx1 decreased after Pkd1-gene disruption and persisted at relatively low levels 
at pre-cystic stages. Interestingly, later on, in cystic kidneys Fjx1 expression dramatically increased. 
The above mentioned roles of the Hippo pathway, together with the opposing expression pattern 
of Fjx1 during epithelial repair and at cystic stages, triggered us to investigate the activity of the 
Hippo pathway during these processes. 
In chapter 5, we provide for the first time evidence for altered activation of the Hippo signal-










































ADPKD, nuclear localization of YAP is observed only in cystic epithelia and dilated tubules but 
not in tubules of pre-cystic kidneys. Increased amounts of YAP-positive nuclei are observed in 
morphological aberrant tubules, dilated tubules, and cysts but not in normal-looking pre-cystic 
tubules. This suggests that aberrant Hippo signaling is not an initiating event in cyst formation 
but accompanies progressive cystic growth.
Our findings, showing altered Hippo signaling during cyst growth, are in line with previous stud-
ies reporting renal cyst formation caused by disturbed Hippo signaling; for example, deregula-
tion of YAP in zebrafish results in pro-nephric cyst formation.18, 19 In addition, mice lacking TAZ 
(Wwtr1), the YAP paralog, show renal cystic disease.19-21
The results in chapter 5 strengthen the concept that during epithelial repair, Four-jointed is 
involved in PCP signaling, while in cystic kidneys it is related to cyst growth. Decreased expres-
sion of Fjx1 is a direct effect of Pkd1 inactivation, while increased Fjx1 and YAP target expression 
can be regarded as an effect of altered signaling during cyst growth, an indirect effect of Pkd1 
inactivation (Fig. 1).
Although both under- and over-expression of YAP, as well as TAZ deficiency, can result in cyst 
formation in animal models, in renal cystic disease it seems to be associated with an increase in 
nuclear YAP, as shown in the different mouse models for ADPKD. This is confirmed by the results 
in patients with ADPKD and ARPKD, demonstrating nuclear localization of YAP in epithelia in the 
majority of cysts. In addition, we showed that, nuclear translocation of YAP in cystic epithelia 
was accompanied by the up-regulation of several postulated targets of YAP in cystic kidneys. Ad-
ditionally, increased nuclear YAP was observed not only in cystic epithelia in ADPKD and ARPKD, 
but also in cystic epithelia in different renal tumors and in liver cysts derived from bile ducts of 
hypomorphic Pkd1 mutants. It is therefore tempting to speculate that altered Hippo signaling is 
a general feature in cystogenesis.
Polycystic kidneys have been elegantly called ‘neoplasia in disguise’.22 Indeed, many pathways 
involved in neoplastic growth are also involved in cyst formation. It is not surprising that a number 
of drugs developed for the treatment of cancer have been shown to be effective in attenuating 
cyst growth in PKD mouse models.23-28 This supports the idea that targeting the Hippo pathway 
could be effective in inhibiting cyst expansion and slowing down progression towards end-stage 
renal failure in PKD. An interesting future experiment will be to explore whether in vivo absence 
of YAP during cyst growth indeed attenuates cyst expansion.
Recently YAP and TAZ were found to be transcription factors involved in relaying mechanical 
signals exerted by ECM rigidity and cell shape. This regulation requires Rho GTPase activity and 
tension of the actomyosin cytoskeleton, but is independent of the Hippo signaling pathway.29 
Interestingly, Pkd1 and Pkd2 are also thought to be involved in mechano-transduction and are 
known to play a role in arterial pressure sensing.30 In addition, the Rho GTPase Cdc42 is up-reg-
ulated in pre-cystic kidneys of Pkd1 conditional knockout mice.10 It would be interesting to inves-
tigate whether the role of YAP in cyst growth is dependent on the Hippo signaling cascade with 






















































Chapter 3 and chapter 5 describe processes involved in cyst initiation and cyst growth, while 
chapter 6 deals with aspects involved in disease progression.
Many mouse and rat models exist for studying the formation and subsequent growth of 
cysts in polycystic kidney disease. However, few models have been described representing the 
phenotype observed in ADPKD patients with advanced stage disease. Clearly, animal models with 
a phenotype that resembles the human pathology are needed to predict accurately the effect of 
potential therapeutics on disease progression in ADPKD patients.
The Pkd1nl,nl mouse model is a model for PKD in which the variation of the phenotype depends 
on the genetic background. Here we report that on a controlled 50%/50% genetic background 
of B6 and Ola (B6Ola), Pkd1nl,nl mice develop large cystic kidneys within 4 weeks and are able 
to survive up to a year. In contrast, to the models homozygous for a Pkd1 inactivating allele, 
B6Ola-Pkd1nl,nl mice, express low levels of Pkd1, are viable, and exhibit grossly normal kidney 
structure, but with dilated proximal tubules at birth.31-35 Although expression of the full length 
Pkd1 transcript is strongly reduced, a 3’-transcript is still produced and it cannot be excluded that 
this may have an effect on renal development and survival.36
In B6Ola-Pkd1nl,nl mice, tubular dilatation and the first cysts could be observed at post-natal day 
1. The first cysts are mostly from proximal tubular origin while later on the majority of cysts 
appeared to be derived from distal tubules, or collecting ducts. 
Interestingly, B6Ola-Pkd1nl,nl mice show an initial increase in renal volume, followed by a decrease 
in renal and cystic volume. The partial regression in renal volume was accompanied by “collapse” 
of cysts, which was paralleled by an increase in fibrosis and influx of inflammatory cells (Fig. 1). In 
addition, apoptosis in cystic epithelia was highest during the period of regression in renal volume, 
suggesting that altered balance between apoptosis and proliferation, favoring apoptosis, may 
play a role in the regression and “collapse” of cysts.
Previously, it was already suggested that apoptosis plays an important role in the pathogenesis 
of PKD. Apoptosis was found to be abundantly present in cystic as well as non-cystic epithelia 
in polycystic kidneys of PKD mouse and patients and was suggested to contribute to the loss 
of normal renal tubules. Although, apoptosis may not be involved in cystogenesis, it may play 
an important role in the progression of the disease and the progressive deterioration of renal 
function.37 The regression of renal volume in our mouse model is a striking phenomenon that 
is also observed in ARPKD patients that survive the neonatal period.38, 39 However, careful 
investigation of renal tissue of ADPKD patients revealed regressing or collapsing cysts, as well as 
cyst remnants. It can be expected that in classical forms of ADPKD, the phenomenon of collapsing 
cysts will not occur extensively. 
Renal volume as clinical end-point used in clinical trials for ADPKD40, 41 was questioned after 
disappointing results of clinical trials with mTOR inhibitors. It was suggested that renal volume 










































on renal volume after low dose sirolimus treatment in the B6Ola-Pkd1nl,nl model.43 In line with 
our data, regarding renal volume regression, and increased fibrosis and inflammatory infiltrates, a 
study revealed that extent of fibrosis and inflammation correlates better with disease progression 
to renal failure than renal volume.44 It would be worthwhile investigating the applicability of if this 
method as clinical end-point in clinical or trials or maybe even in daily clinical practice.
Models, in which almost all nephrons develop cysts simultaneously in a relative short time span, 
are useful to study cyst initiation and progression. However, models closely resembling advanced 
stage human ADPK are of outmost importance, especially to better predict the effect of new 
therapeutics. 
With regard to the characteristic aspects of human ADPKD disease progression, fibrosis and 
inflammation,45 the B6Ola-Pkd1nl,nl model shows great similarity with the human ADPKD renal 
pathology. Even more, when onset and degree of nephrons involved is taken into account, the 
model mostly resembles patients with two incomplete penetrant alleles of PKD1 and PKD2, 
showing a severe early onset renal cystic phenotype.46-48 It would be interesting to identify the 
course of the disease renal volume changes in these patients. 
The B6Ola-Pkd1nl,nl model not only resembles the phenotype of human ADPKD ; it also shows 
altered activity of canonical Wnt signaling, TGF-β signaling, the mTOR pathway and Hippo 
signaling, all of them are found to be altered in models for PKD and , importantly, in renal tissue 
ADPKD patients.43, 49-52, 52-57 
In conclusion, the renal cystic phenotype of B6Ola Pkd1nl,nl mice seems to reflect the phenotype 
of patients with early onset PKD as result of two hypomorphic mutations. In addition, this model 
showed that regression of cysts and renal volume occurs, implying that renal volume may not be 
a good predictor of progression to renal failure and end stage renal disease. 
General discussion
In this thesis it was shown that injury induced proliferation is involved in cyst formation. Altered 
PCP and Wnt signaling create a permissive condition in which requires an additional factor 
setting cyst formation in motion. Abnormal integrity of the newly formed cells, resulting from 
the absence of Pkd1 expression during repair, might be such a factor (Fig. 1). As the base of this 
aberrant cellular integrity lies within the epithelial repair it would be interesting to investigate 
the process of repair more carefully, as in our study no differences at the end of repair between 
controls Pkd1 heterozygotes and conditional Pkd1-deletion mice were observed, while others 
did for Pkd1 and Pkd2 mutant mice with other types of injury.58, 59 Possibly, differences can be 
observed in earlier phases, before repair approaches completion. 
In ADPKD patients injury induced proliferation may occur as well. The injury causing factors can 





















































surrounded by relatively normal renal parenchyma. These cysts compress the surrounding tissue 
and are a source for oxidative stress and injury, causing proliferation. When the disease progresses 
more, inflammatory cells as well as the presence of fibrotic tissue become a source of injury and 
proliferation. This accelerates the cyst formation in healthy tubules and in its turn provides more 
sources of injury and proliferation. 
Then we showed that the Hippo signaling pathway is also implicated in cyst growth. This 
pathway is known to be implicated in organ size control, tumorigenesis and recently also tissue 
regeneration and stem cell self renewal. Although a complex network of signaling pathways is 
involved in cyst growth, finding treatment for ADPKD may benefit from the great promise that 
the Hippo-YAP pathway holds as a target for anti-cancer therapy and regenerative medicine. 
Finally disease progression was studied and showed that the B6Ola-Pkd1 mouse model showed 
regression of renal and cystic volume followed by fibrosis and inflammation. This was not seen in 
the conditional Pkd1-deletion model. In these mice fibrosis is hardly observed probably due to the 
rapid cyst formation in all most all nephrons synchronously, leading to renal failure. Furthermore, 
in these mice Pkd1 deletion is only achieved in renal epithelial cells while in B6Ola-Pkd1 mice all 
cells express low levels of Pkd1, including fibroblast and inflammatory cells. As altered activation 
of Cdc42, a protein involved in cell migration, was found to be involved in cystogenesis in 
Pkd1 mutant mice10, it would interesting to investigate the effect of Pkd1 deletion in fibroblast 
and inflammatory cells and their role in ADPKD disease progression. In addition, macrophage 
depletion studies in mice with PKD provide evidence for an accelerating role of macrophages 
in growth of renal cysts.60 However, in the Pkd1 model used only renal epithelial cells were 
depleted of polycystin-1, while the Pkd2 model all cells have reduced polycystin-2 expression. As 
inflammation and interstitial fibrosis, in which macrophages play an important role, are important 
in ADPKD disease progression, therapies also targeting macrophage recruitment into the kidney 
may be beneficial in the treatment of ADPKD disease progression.
Due to the similarities with the human ADPKD renal pathology the B6Ola-Pkd1 mice provide a 
suitable model to study the effect of potential therapeutic drugs on ADPKD disease progression. 
In addition this model showed that renal volume is a poor clinical end point as surrogate for 
disease progression. 
Taken together cyst formation, cyst growth and ADPKD disease progression are complex processes 
regulated by many signaling networks. This not only provides many targets for therapeutic 
intervention but is also a difficulty at the same time. Aiming for a single therapeutic target will 
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Nederlandse samenvatting voor niet-ingewijden
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is een van de meest voorkomende 
erfelijke aandoeningen. Deze ziekte heeft als belangrijkste kenmerk de vorming van met vloeistof 
gevulde cysten (vochtblazen) in de nieren. Maar ook in de lever en alvleesklier kunnen cysten 
ontstaan. Vaak hebben patiënten ook last van een hoge bloeddruk en kunnen er zwakke plekken 
in de bloedvaten optreden. Over een periode van tientallen jaren vormen er zich duizenden met 
vocht gevulde cysten die de plaats innemen van het gezonde nierweefsel, wat resulteert in een 
slechter functioneren van de nieren. Uiteindelijk zijn de meeste patiënten tussen hun 50e en 60e 
levensjaar aangewezen op nierdialyse omdat er niet genoeg gezond nierweefsel over is om alle 
afvalstoffen uit het bloed te filteren. Op dit moment zijn er nog geen medicijnen beschikbaar om 
de vorming van de cysten in de nieren te vertragen of te voorkomen en daarmee een volledige 
uitval van de nierfunctie te voorkomen. 
Om medicijnen te kunnen ontwikkelen om deze patiënten te kunnen behandelen is het nodig om 
het mechanisme te begrijpen wat ten grondslag ligt aan de cystenvorming en het ontwikkelen 
van volledige uitval van de nierfunctie. Hiervoor is wetenschappelijk onderzoek nodig.
 Het doel van mijn promotieonderzoek was om te onderzoeken hoe de cysten in de nier nu 
ontstaan en welke factoren hier een rol bij spelen. Ook heb ik de groei van cysten bestudeerd en 
de ontwikkeling bekeken van een nier met cysten die nog voldoende functioneert naar een nier 
met volledige uitval van de nierfunctie.
ADPKD wordt veroorzaakt door een fout (mutatie) in het PKD1- of PKD2-gen. Patiënten 
met ADPKD hebben in hun DNA één foute en één goede kopie van het PKD1 of PKD2 gen, 
terwijl gezonde mensen twee goede kopieën van hun ouders hebben gekregen. De nieren zijn 
opgebouwd uit nefronen; de functionele eenheden van de nier. Een nefron bestaat uit een filtertje 
en een nierbuisje dat de urine opvangt. In de nieren van ADPKD patiënten wordt een probleem 
veroorzaakt door de cellen die de binnenkant van de nierbuisjes bekleden. Om de goede opbouw 
van de nierbuisjes te behouden zijn er gebalanceerde hoeveelheden nodig van het polycystine-1 
(PC1) en 2 (PC2) eiwit. Het recept om deze eiwitten te maken staat beschreven in respectievelijk 
het PKD1- en PKD2-gen. Wetenschappelijk onderzoek heeft laten zien dat bij muizen het 
uitschakelen van één Pkd1 kopie niet resulteert in de vorming van ernstige cystennieren, terwijl 
het uitschakelen van beide kopieën de dood voor de geboorte of vlak daarna tot gevolg heeft. 
Dit heeft geleid tot de hypothese dat in het geval van ADPKD, in een subset van de cellen die 
de nierbuisjes bekleden, de hoeveelheid van PC1 of PC2 onder een kritische waarde moet dalen 
om cystenvorming als gevolg te hebben. Dit kan veroorzaakt worden door een mutatie in of 
verminderde aanmaak van PC1 of 2 vanaf de gezonde kopie, respectievelijk de zogenaamde 
“second hit”, of haploinsuffieciëncy genoemd. 
Binnen de onderzoeksgroep waar ik gewerkt heb aan mijn promotieonderzoek, is een muismodel 










































op een willekeurig moment kan worden uitgeschakeld. Dit model wordt het induceerbare Pkd1-
deletie model genoemd. Op deze manier is het mogelijk om het dodelijke effect van volledige 
uitschakeling te omzeilen en cystenvorming te bestuderen. 
Uit experimenten met dit diermodel bleek dat het belangrijk was of de cellen in het nierbuisje 
aan het delen waren of niet. In hele jonge muizen is de nier nog aan het groeien, en worden de 
nierbuisjes langer door deling van de cellen die het buisje bekleden. Als in deze hele jonge muizen 
het tweede Pkd1 kopie wordt uitgeschakeld, krijgen deze muizen zeer ernstige cystennieren. 
Wanneer het gen in volwassen muizen, waarin de cellen van de nierbuisjes nauwelijks nog delen, 
wordt uitgeschakeld, ontstaan er nauwelijks cysten in de nieren en duurt het bovendien erg lang 
voordat deze ontstaan. Hieruit volgde de hypothese dat de status van de mate van celdeling 
van de cellen die de nierbuisjes bekleden, belangrijk is voor de snelheid waarmee cystennieren 
ontstaan. 
Hoofdstuk 3 van dit proefschrift beschrijft een test van deze hypothese. In volwassen muizen werd 
eerst het gezonde Pkd1 kopie uitgeschakeld. Vervolgens hebben we celdeling van de cellen in de 
nierbuisjes veroorzaakt. Er werd met een chemische stof, genaamd DCVC, schade aangebracht 
aan de cellen van de nierbuisjes. Hierdoor gaan er cellen dood en gaan de overgebleven cellen 
deze schade vervolgens repareren door te delen en de lege plaatsen weer op te vullen. De door 
de schade veroorzaakte celdeling bleek inderdaad de cystenvorming in de nieren aanzienlijk te 
versnellen. Daarnaast hebben we aangetoond dat er na volledige uitschakeling van het Pkd1-gen 
er een aantal vroege veranderingen optreden in bepaalde signaleringsroutes.
Voor het goed functioneren van een cel is het belangrijk dat de informatie van buiten de cel 
verwerkt wordt in de cel en dat deze daar op de juiste manier op reageert, door bijvoorbeeld 
bepaalde eiwitten te produceren. Vaak wordt in het lichaam informatie verstuurd via chemische 
stoffen die kunnen binden aan de “ontvangers” aan de buitenkant van de cel. De “ontvangers” 
aan de buitenkant van de cel worden receptoren genoemd, en de stoffen die eraan binden, 
liganden. Deze liganden en receptoren werken volgens een sleutel-slot principe. Alleen met de 
goede sleutel gaat het slot open en volgt er een cascade van reacties in de cel die tot de benodigde 
reactie van de cel leidt. De eiwitten en processen die nodig zijn voor een specifieke cascade van 
reacties op een bepaald ligand, worden samen een signaaltransductie route of signaleringsroute 
genoemd. 
Als vroege verandering na uitschakeling van het Pkd1-gen werd verhoogde activatie van de Wnt-
signaleringsroute gevonden. Deze Wnt-signaleringsroute is belangrijk tijdens de embryonale 
ontwikkeling.Verhoogde activiteit van deze route zorgt o.a. voor verhoogde celdeling. Een andere 
verandering is een verstoring in de planar cell polarity. De cellen die de nierbuisjes bekleden, 
hebben een boven- en een onderkant. De onderkant is de kant waarmee de cel vast zit aan de 
wand van het nierbuisje. De bovenkant van de cel is naar de ruimte aan de binnenkant van het 
nierbuisje gericht. 
Naast deze vorm polariteit, die haaks op de wand van het nierbuisje staat, is er ook polariteit 






















































polarity, geeft de cel informatie over wat de lengte- en breedterichting van het nierbuisje is. Dit 
is belangrijk om te zorgen dat bijvoorbeeld tijdens de ontwikkeling van de nierbuisjes de buisjes 
langer worden, maar dat de diameter gelijk blijft. Ook bij herstel zorgt planar cell polarity ervoor 
dat het nierbuisje de goede vorm blijft houden. In hoofdstuk 4 wordt een techniek die wij 
gebruikt hebben om de planar cell polarity te bestuderen uitgebreid beschreven.
De vroege veranderingen na het uitschakelen van het Pkd1-gen zijn (gedeeltelijk) nodig voor de 
vorming van cysten, maar zijn op zichzelf niet genoeg; er is nog een additionele factor nodig. De 
verstoorde opbouw van nieuwe cellen na celdeling in afwezigheid van PC1 zou die factor kunnen 
zijn. Deze verstoorde opbouw zorgt ervoor dat nog meer signaleringsroutes ontregeld raken en 
de cellen beginnen te delen en een uitstulping vormen in het nierbuisje. Uit deze uitstulping 
ontstaat uiteindelijk een afgesloten cyste die in grootte verder toeneemt. 
Een van de onderzochte genen, waarvan het product in de regulatie van planar cell polarity een 
rol speelt, wekte onze interesse. Dit eiwit, genaamd ”fourjointed”, maakt niet alleen deel uit 
van de signalering die planar cell polarity reguleert, maar ook van de Hippo-signaleringsroute. 
De Hippo-signaleringsroute speelt een rol bij het controleren van de grootte van organen in de 
fruitvlieg en is ook van belang bij verschillende vormen van kanker in de mens. In hoofdstuk 5 
is onderzocht of de Hippo-signaleringsroute een aandeel heeft in het proces van cystenvorming. 
Er werd geen verandering gevonden in de Hippo-signaleringsroute vóór de initiatie van 
cystenvorming. Echter in verwijde nierbuisjes en cysten werd wel een verandering waargenomen 
in de Hippo-signalering. Hieruit kan geconcludeerd worden dat de Hippo signaleringsroute geen 
rol speelt in de initiatie van cystenvorming in de nieren, maar samen gaat met de groei van cysten 
en zeer waarschijnlijk ook bijdraagt aan die groei.
Naast de initiatie van cystenvorming en de groei van cysten komt ook de progressie van ADPKD in 
dit proefschrift aan bod. Hoofdstuk 6 beschrijft factoren die belangrijk zijn bij de progressie van 
cystennieren naar levensbedreigende uitval van de nierfunctie. Verschillende muismodellen, zoals 
het induceerbare Pkd1-deletie model, zijn beschikbaar om de vorming en daaropvolgende groei 
van cysten te bestuderen. Echter, er zijn weinig modellen beschreven die het uiterlijk, fenotype, van 
de humane cystennieren in een gevorderd stadium van de ziekte weerspiegelen. In hoofdstuk 6 
wordt een muismodel dat maar 15-20% van de normale hoeveelheid PC1 aanmaakt, het Pkd1nl,nl 
model, beschreven. Deze muizen hebben bij de geboorte verwijde nierbuisjes en in een periode 
van 4 weken ontwikkelen ze grote cystennieren maar ze kunnen 12 maanden oud worden. In de 
eerste 4 weken werd een grote toename in het volume van de nieren waargenomen, daarna nam 
het niervolume weer af. Tegelijkertijd was er sprake van regressie van cysten, ze werden kleiner, 
ze stortten als het ware in. Deze afname in niervolume en collaps van cysten, ging gepaard 
met een toename in fibrose, de vorming van littekenweefsel, en later een toename van het 
aantal ontstekingscellen. Op een leeftijd van 4 weken, als het niervolume maximaal is, is ook 
gecontroleerde celdood het hoogst. Dit betekent dat gecontroleerde celdood een rol zou kunnen 










































De collaps en het verdwijnen van cysten in het Pkd1nl,nl muismodel wordt ook waargenomen in 
nierweefsel van ADPKD patiënten, echter op veel minder grote schaal.
Met betrekking tot de karakteristieke aspecten van het ziektebeloop van ADPKD, fibrose en 
ontsteking laat het Pkd1nl,nl muismodel grote overeenkomsten zien met de nieren van ADPKD 
patiënten. Daarnaast heeft dit model laten zien dat regressie van niervolume en cysten 
plaatsvindt, wat impliceert dat het volume van de nier geen goede voorspellende factor is voor 
het ontwikkelen van volledige uitval van de nierfunctie.
Uit de resultaten beschreven in dit proefschrift kunnen we concluderen dat de mate van celdeling 
van de cellen van de nierbuisjes belangrijk is voor de vorming van cysten in de nier.
De vroege veranderingen die optreden direct na het uitschakelen van het Pkd1-gen maken de 
cellen vatbaar voor cystenvorming, maar zijn alleen niet voldoende om tot cystenvorming te 
leiden. Celdeling van de cellen van de nierbuisjes is noodzakelijk om deze cellen daadwerkelijk 
tot cystenvorming aan te zetten. Afwijkende opbouw van de nieuw gevormde cellen zou hier 
een belangrijke rol in kunnen spelen. De basis van deze afwijkende opbouw ligt in het herstel 
na schade en het zou interessant zijn om het herstelproces na schade in meer detail te bekijken.
Vervolgens hebben we laten zien dat de Hippo-signaleringsroute samen gaat met de groei van 
cysten en mogelijk ook bijdraagt aan die groei. Vervolg experimenten zijn nodig om te laten zien 
dat deze signaleringsroute daadwerkelijk bijdraagt aan de groei van cysten door in te grijpen 
in deze signaleringsroute in één van de muismodellen voor ADPKD. Als blijkt dat de Hippo-
signaleringsroute inderdaad bijdraagt aan cystengroei, is dit een nieuw aangrijpingspunt voor 
therapie om de cystengroei te remmen. 
Ten slotte blijkt het Pkd1nl,nl muismodel grote overeenkomst te vertonen met de humane pathologie 
van ADPKD. Dit muismodel laat een afname van het niervolume en collaps van de cysten zien, die 
gepaard gaat met de vorming van littekenweefsel. 
De waargenomen afname van niervolume impliceert dat niervolume geen goede voorspellende 
factor is voor het ontwikkelen van volledige uitval van de nierfunctie en zou niet als enige 
parameter gebruikt moeten worden in klinische trials om de effectiviteit van een kandidaat 
geneesmiddel vast te stellen.
Dit proefschrift laat zien dat cystenvorming, cystengroei en ADPKD ziekteprogressie complexe 
processen zijn, die door veel factoren beïnvloed worden. Dit biedt niet alleen veel aangrijpingspunten 
voor therapeutische interventie, maar is tegelijkertijd een moeilijkheid. Therapeutische interventie 
op slechts één aangrijpingspunt zal hoogst waarschijnlijk niet succesvol zijn. Voor de behandeling 
van ADPKD is eerder een “multi-target” aanpak nodig.
Dit promotieonderzoek heeft bijgedragen aan het inzicht in het onstaan en de groei van 
cysten en de progressie van ADPKD. Dit is slechts een kleine stap vooruit in de zoektocht naar 
een behandeling voor ADPKD. Zoals gebruikelijk in wetenschappelijk onderzoek levert een 
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